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ABSTRACT 
Prostate cancer (PCa) is the second leading cause of cancer and cancer related deaths in 
U.S. men; thus, identifying strategies to reduce PCa incidence could have a significant impact on 
public health.  
Epidemiological studies have supported the hypotheses that dietary intake of soy foods or 
tomato products is associated with a reduced risk of PCa. The efficacy of combinations of foods 
and bioactives for enhanced health benefits is of clinical interest, but the interactions between 
foods rich in bioactives for the inhibition of PCa are largely unknown.  To evaluate the 
bioavailability of tomato carotenoids and soy germ isoflavones when consumed alone or 
together, male Copenhagen rats were randomized to consume: AIN-93G control, 10% tomato 
powder (TP), 2% soy germ (SG) or 10% tomato powder + 2% soy germ (TP+SG) for 7 days or 
25 weeks. In the 7-day trial, rats consuming TP+SG had significantly lower serum phytoene, 
phytofluene, and lycopene compared to rats consuming TP alone (p<0.05). In the 25-week trial, 
lycopene bioaccumulation was significantly lower in the testes, seminal vesicles and ventral 
prostate of rats that consumed TP+SG compared to TP alone (p<0.05). Reduced carotenoid 
bioaccumulation was not explained by mRNA expression of scavenger receptor class B type I (a 
protein involved in carotenoid absorption) or carotenoid metabolizing enzymes in the prostate, 
liver or duodenal mucosa. Hepatic lipid accumulation and serum cholesterol were not 
significantly different between groups, suggesting that differences in carotenoid bioaccumulation 
were likely not due to effects on intestinal micellerization or lipid absorption. Significantly 
higher urinary isoflavone excretion in the TP+SG group compared to the SG group was not 
explained by differences in activity or expression of hepatic detoxification enzymes. Soy 
isoflavones and tomato carotenoids have distinctly different mechanisms of absorption, yet, 
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long-term combined consumption of TP+SG resulted in reduced carotenoid bioaccumulation and 
increased urinary isoflavone excretion than when each food was consumed separately.  
After identifying a food-food interaction in the bioavailability study, the efficacy of 
dietary tomato and soy germ, alone and in combination, for the inhibition of PCa was evaluated 
in the TRAMP model of PCa.  At 4 weeks of age, male TRAMP mice were randomized to 
consume: AIN-93G control, 10% TP, 2% SG or TP+SG for 14 weeks.  Serum and testicular 
lycopene concentrations were significantly lower in TP+SG fed mice compared to mice fed TP 
alone, supporting our previous finding of reduction of carotenoid bioavailability by consumption 
of SG. Equol, produced from the metabolism of daidzein by intestinal microbiota, was the 
predominant isoflavone in the serum and prostate in SG fed mice. 100% of mice fed the control 
diet had PCa, while PCa incidence was significantly lower in mice consuming TP (61%, 
p<0.001), SG (66%, p<0.001) and TP+SG (45%, p<0.001).  Although the protection offered by 
the combination of TP and SG was not synergistic, it was quantitatively the most effective 
intervention.   
Consumption of cruciferous vegetables, such as broccoli, has been suggested to reduce 
the risk of aggressive PCa.  Clinical evidence suggests expression of markers of the epithelial-
mesenchymal transition (EMT) is associated with a more invasive and aggressive PCa.  The goal 
of the project was to investigate the effects of consumption of standard broccoli and methyl-
jasmonate (MeJa) treated broccoli, a broccoli higher in bioactive, indole-glucosinolates, on 
expression of EMT markers in TRAMP mice with well-differentiated adenocarcinoma.  
Immunohistochemical analysis of E-cadherin and N-cadherin across a range of pathology in the 
TRAMP model suggests that the loss of E-cadherin and the gain of N-cadherin are predictive of 
metastasis.  A trend of higher prostatic E-cadherin expression by standard broccoli (p=0.06) but 
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not MeJa broccoli (p=0.5) was identified. Compared to control-fed TRAMP mice, prostatic 
mRNA expression of N-cadherin was approximately 2-fold lower in mice fed either standard 
(p=0.04) or MeJa (p=0.02) broccoli. MeJa broccoli did not provide any additional benefit 
compared to standard broccoli, suggesting that the indole-glucosinolates are not responsible for 
modulation of markers of EMT by broccoli.   
Mechanisms by which the combination of tomato and soy germ, alone and in 
combination, are protective against PCa or by which broccoli can modulate expression of EMT-
related markers are yet to be elucidated and require further investigation. Combinations of foods 
such as tomato and soy germ may result in positive food-food interactions, providing added 
protection against prostate carcinogenesis.  Whole foods, such as broccoli, may modulate the 
molecular profile of existing PCa, reducing the risk of cancer progression and associated 
mortality.  Overall, our findings suggest that dietary interventions with whole foods and 
combinations of foods are effective and safe strategies for prevention of PCa incidence or 
progression in an animal model. 
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CHAPTER 1 
LITERATURE REVIEW 
Introduction 
Prostate cancer (PCa) is the leading cause of new cancer cases and second leading cause 
of cancer deaths in U.S. men (1).  It is estimated that one in six men will get PCa in his lifetime. 
Over 95% of PCa cases are adenocarcinomas, originating from epithelial cells with secretory 
properties (2). The pathogenesis of PCa is: normal prostate epithelium  prostatic inflammatory 
atrophy (PIA)  prostatic intraepithelial neoplasia (PIN)  prostatic adenocarcinoma (PCa) 
hormone-refractory, metastatic PCa (3).  There are unavoidable risk factors for PCa including 
age, race, nationality and family history; however, there are several modifiable risk factors 
including obesity, smoking and diet (4). The AICR /WCRF recently estimated that one in three 
cancers could be prevented by lifestyle changes, including eating a diet rich in fruits and 
vegetables (5). Due to the high prevalence of PCa, identifying strategies to reduce PCa risk could 
have a significant impact on public health.   
Tomato and Soy Products for Prevention of Prostate Cancer 
The 2007 AICR/WCRF report, a systematic review of the literature evaluated by an 
expert panel, concluded that foods containing lycopene “probably protect against prostate 
cancer” and there is “limited-suggested evidence” that pulses, including soy and soy products 
reduce the risk of PCa (6). The evidence supporting the protective effects of soy and foods 
containing lycopene is noteworthy because numerous other dietary factors were evaluated in the 
report, and the panel only identified selenium, foods containing selenium, foods containing 
vitamin E and α-tocopherol as having a similar strength of evidence.  
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Tomato and Prostate Cancer - Epidemiology 
The first association of tomato product consumption and reduced risk of PCa was 
identified in the Health Professional’s Follow-Up Study (7). The combined consumption of 
tomatoes, tomato juice, tomato sauce and pizza was associated with a significantly reduced risk 
of total (RR=0.65) and advanced PCa (RR=0.47). Lycopene, raw tomatoes, tomato sauce and 
pizza were each associated with a reduced risk of PCa. The results from this trial sparked a surge 
of reports investigating the inverse correlation between tomato/lycopene consumption and PCa 
risk. A 2004 meta-analysis of twelve case-control and three cohort studies identified a 
significantly reduced risk of PCa by inclusion of both raw tomatoes (RR=0.89) and cooked 
tomato products (RR=0.81) in the diet (8).  However, more recent studies in the Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial (9) and the Prostate Cancer Prevention Trial (10) 
have not identified a significant association between tomato consumption and risk of PCa. 
Although epidemiological evidence has yielded mixed results, the 2007 AICR/WCRF report’s 
overall evaluation of the evidence states that foods containing lycopene “probably protect against 
prostate cancer” (6). 
Tomato and Prostate Cancer – In vitro evidence 
Tomatoes contain nutrients such as Vitamin C and folate and are a rich source of dietary 
bioactives, primarily polyphenols and the carotenoids lycopene, β-carotene, phytoene, and 
phytofluene. Although tomatoes contain many bioactive compounds, research has primarily 
focused on the anti-carcinogenic properties of lycopene, the primary carotenoid found in 
tomatoes.  In vitro, bioactives in tomato have been shown to induce cell-cycle arrest, induce 
Phase II enzymes, function as antioxidants, modulate growth factor signaling, and increase cell-
cell communication via gap junctions (11, 12).   
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Tomato and Prostate Cancer – Preclinical Trials 
As reviewed in Table 1.1, there are only a few trials that have investigated tomato 
products in an animal model of PCa. Tomato powder consumption increased survival and 
reduced carcinogenesis in three different rodent models of PCa (13-16). Interestingly, tomato 
paste alone has not been protective against PCa (14, 17); thus, tomato seeds and skins, which are 
not in tomato paste, may be significant contributors to the anti-cancer activity of tomatoes. 
Tomato paste plus ketosamine (FruHis), a carbohydrate derivate in dehydrated tomato products, 
significantly increased PCa free survival; therefore, ketosamines in tomato powder may also 
have anti-cancer activity (14). The few preclinical trials investigating tomato products support 
epidemiological findings that consumption of whole tomatoes may be protective against PCa.  
Table 1.1. Summary of Preclinical Trials with Tomato Products 
Study Tomato Product Animal Model Outcome 
Pannellini 
2010 (13) 
10% tomato powder TRAMP ↑ survival, ↑ area of normal histology,  
↓ PIN and PCa 
Konijeti 
2010 (17) 
12.8% tomato paste TRAMP Ф  PCa incidence 
Mossine 
2008 (14) 
10% tomato paste, 10% 
tomato powder,  
10% tomato paste + 2% 
FruHis 
NMU+testosterone Tomato powder and tomato paste + 
FruHis: ↑survival 
Tomato paste alone: Ф survival  
Canene-
Adams 2007  
(15) 
10% tomato powder 
 
 
Dunning R3327-H  ↓ tumor weight , ↑ apoptosis, ↓ 
proliferation 
Boileau 
2003 (16) 
10% tomato powder NMU+testosterone ↑ PCa-free survival 
NMU = N-methyl-N-nitrosourea 
TRAMP= transgenic adenocarcinoma of the mouse prostate 
↓ = significantly reduced 
↑ = significantly increased 
Ф = No significant effect 
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Tomato and Prostate Cancer – Clinical Trials 
Several clinical trials have investigated lycopene supplementation in men with PCa or at 
risk for PCa (18); however, few clinical trials have investigated a dietary intervention with 
tomato products. As reviewed by Ellinger et. al, the majority of short-term interventions (1 week 
– 26 days) with tomatoes or tomato products did not significantly affect markers of DNA 
damage in healthy individuals (19). In men with PCa (n=32), a three week intervention with 
tomato sauce (30mg lycopene/day) significantly reduced serum prostate specific antigen (PSA) 
and markers of oxidative DNA damage in the prostate (20) and significantly increased apoptosis 
(21). However, in a double-blind, randomized controlled trial with a larger sample size (n=105), 
three weeks of tomato sauce supplementation did not significantly reduce serum PSA or markers 
of oxidative stress in the prostate (22). Tomato paste supplementation, providing 13mg 
lycopene/day for ten weeks, significantly reduced plasma PSA by ~11% in men with benign 
prostatic hyperplasia (23). A tomato-based supplement (tomato juice or paste) providing 30mg 
lycopene/day for an average of 3 months, did not significantly affect serum PSA in men with 
androgen-independent PCa, indicating that tomato consumption may not be protective in later, 
more aggressive stages of the disease (24). Overall, there is conflicting clinical evidence as to 
whether intervention with tomato products can effectively reduce prostate carcinogenesis.  
Soy and Prostate Cancer – Epidemiology 
Many epidemiological trials have evaluated soy isoflavones or soy food consumption on 
risk of PCa. As reviewed in a 2009 meta-analysis of 5 cohort and 8 case-control studies, total soy 
intake (OR = 0.9) and nonfermented soy foods (OR = 0.75) were associated with a reduced risk 
of PCa (25). Another 2009 meta-analysis which included 14 studies (5 cohort, 9 case-control) on 
soy intake and 8 studies (2 cohort, 6 case-control) on soy isoflavone intake, identified a similar 
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reduced risk of PCa by soy (26). Total soy (RR/OR = 0.74) and nonfermented soy foods (RR/OR 
= 0.70) were significantly associated with a reduced risk of PCa, yet no association was seen by 
fermented soy foods (RR/OR = 1.02) or soy isoflavone intake (OR/RR = 0.88, p=0.09). Further 
analysis of the soy isoflavone intake studies identified a reduced risk of PCa in Asian 
populations (RR/OR = 0.52) but not Western populations (OR/RR = 0.99), which is likely 
attributed to the high isoflavone intake in Asian populations (mg/day) compared to Western 
populations (µg/day). Numerous studies have identified an inverse relationship between soy 
intake and PCa, supporting the 2007 AICR/WCRF report’s finding of “limited-suggestive 
evidence” that pulses, including soy and soy products, reduce the risk of PCa (6). 
Soy and Prostate Cancer – In vitro evidence 
Soybean (Glycine max) is a source of complete protein, dietary fiber, poly- and 
monounsaturated fatty acids, along with numerous bioactives including isoflavones, saponins, 
phytosterols and lignans.  Isoflavones are believed to significantly contribute to the reduced risk 
of PCa associated with soy consumption. The primary isoflavones in soy are genistein, daidzein 
and glycitein and are classified as phytoestrogens due to the ability of these compounds to bind 
to estrogen receptors (27). A large body of mechanistic research suggests soy isoflavones may 
inhibit proliferation, increase apoptosis, and inhibit tumor growth and angiogenesis.  They also 
appear to be anti-inflammatory, modulate activity of detoxification enzymes, and may modulate 
steroid hormone levels and receptors in the prostate (27-29). 
Soy and Prostate Cancer – Preclinical Trials 
Soy protein isolate (SPI) has been the primary soy food studied in animal trials (Table 
1.2). SPI, a highly refined soy product, is approximately 90% protein, with the majority of 
nonprotein components of the soybean removed (30). In the Lobund-Wistar (L-W) rat model, 
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which spontaneously develops prostate-seminal vesicle tumors with age, SPI significantly 
reduced tumor incidence (31-33). SPI consumption initiated later in life (12 months of age) was 
also able to prevent or reverse PCa in the L-W model; therefore, consumption of soy in 
adulthood, as well as lifelong consumption, may be protective against PCa (31).  Isoflavones 
may be largely responsible for the protection seen by SPI, since alcohol-washed SPI, which is 
low in isoflavones (20 mg/kg diet), was not effective at reducing tumor growth (34). The few 
trials with soy phytochemical concentrates or isoflavone mixtures provided a significant amount 
of isoflavones in the diet (up to 2600 mg/kg diet) and were effective at reducing PCa incidence 
and/or tumor growth (34-37). Several potential anti-carcinogenic mechanisms of soy and soy 
phytochemicals have been identified in vivo including reduced serum testosterone (31-33), 
increased apoptosis (34, 38), reduced proliferation (37) and reduced angiogenesis (34, 37). 
Overall, the majority of soy products and isoflavone/phytochemical mixtures investigated in 
preclinical models have been effective at reducing tumor incidence and growth.  However, 
further research is needed to determine the efficacy of other soy foods and products.  
Soy and Prostate Cancer – Clinical Trials 
Dietary interventions with soy rich diets, soy protein isolate-based beverages, or soy 
bread, have shown limited success at reducing serum PSA in either healthy, older adults or men 
with PCa (39-44).  In men with high-grade PIN or low-grade PCa (n=58), consumption of soy 
protein isolate with or without isoflavones for 6 months resulted in significantly lower PCa 
incidence than the milk protein group (39). The majority of soy interventions have focused on 
soy protein isolates with limited biomarkers of efficacy other than PSA. Much like the evidence 
for tomato product consumption, clinical trials have yielded mixed and limited results as to the 
efficacy of a soy based intervention for prevention of PCa.  
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Safety and Potential Bioactivity of Soy Germ 
The majority of preclinical and clinical intervention trials with soy have utilized soy 
protein isolate; however, the efficacy of this soy product should not be extrapolated to all soy 
products. Soy germ, the hypocotelydon of soy, is separated during milling of whole soybeans, 
and is a concentrated source of soy bioactives including isoflavones, saponins, and phytosterols.  
In contrast to soy protein isolates, concentrations of daidzein and glycitein in soy germ are 
considerably higher than genistein.  In whole soybean products, the isoflavone profile (aglycone 
equivalents) is typically 40% daidzein, 50% genistein and 10% glycitein. In contrast, the 
isoflavone profile (aglycone equivalents) of soy germ is 50% daidzein, 39% glycitein and 10% 
genistein. The higher concentration of daidzein in soy germ may result in increased production 
of the highly bioactive metabolite (S)-equol.  Soy germ, a phytochemical rich product high in the 
equol precursor daidzein, should be further investigated for potential anti-cancer activity. 
Frutarom, the company that manufactures the SoyLife ® brand of soy germ products, has 
conducted several studies to evaluate the safety of their products. In rats, doses up to 2000 mg 
soy germ/kg diet were not genotoxic (45). Another trial determined the No Observed Adverse 
Effect Level for soy germ was 1000 mg /kg/day in rats, which is equivalent to 70 g SoyLife ® a 
day in humans (45). A 2-year clinical trial that administered 80-120 mg aglycone equivalent 
isoflavones a day through a soy germ based supplement was safe in postmenopausal women 
(46). Soy germ supplementation providing 116 mg aglycones a day for 12-weeks in healthy men 
was well tolerated and no adverse effects were reported (47). In general, experimental evidence 
suggests that consumption of soy germ products and/or supplements can be considered safe
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Table 1.2. Summary of Preclinical Trials with Soy Products 
Study Soy Product Animal Model Outcome 
Wang 
2012 (48) 
10% or 20% 
kcalories 
from SPI 
Mouse xenograft 
with PC-3 cells 
↓ tumor volume 
Hsu 
2011(49) 
20% SPI Noble rat model  Ф prostatic epithelium layer thickness, 
stromal volume or hyperplasia incidence  
Cohen 
2003 (50) 
5%, 10%, or 
20% SPI 
Dunning R-
3327-AT-1 rat 
tumors 
Ф tumor growth by any dose 
Zhou  
2002 (34) 
20% alcohol-
washed SPI 
SCID mice 
orthotopically 
implanted with 
LNCaP cells 
Ф tumor weight, ↑ apoptosis, ↓ microvessel 
density 
Pollard 
2001 (31) 
20% SPI L-W ↓ P-SV tumor incidence, ↓ serum testosterone   
Pollard 
2000 (32) 
20% SPI L-W ↓ P-SV tumor incidence, ↓ prostate weight, ↓ 
serum testosterone 
Pollard 
2000 (33) 
20% SPI L-W+ NMU ↓ P-SV tumor incidence, ↓ prostate weight, ↓ 
serum testosterone 
Bylund 
2000 (38) 
22.5% SPI Mouse xenograft 
with LNCaP 
cells 
↓ tumor weight, ↑ apoptotic index 
Landstrom 
1998 (51) 
33% soy 
flour 
Dunning R-3327 ↓ tumor volume 
 
9 
 
Table 1.2 continued 
Ф = No significant effect 
↓ = significantly reduced 
↑ = significantly increased 
SPI = Soy protein isolate 
L-W = Lobund-Wistar rat 
NMU = N-methyl-N-nitrosourea 
PhIP=  2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
P-SV = Prostate-Seminal Vesicle
Soy Isoflavone/Phytochemical Mixtures 
McCormick 
2007 (35) 
200 or 
2000mg/kg 
soy isoflavone 
mixture  
NMU+testosterone 
in  Wistar-
Unilever rats 
↓ PCa incidence by 2000mg/kg 
isoflavones 
Ф by 200 mg/kg isoflavones 
Hikosaka 
2004 (52) 
0.25% soy 
isoflavone 
mixture 
PhIP induced 
carcinogenesis in 
F344 rats 
↓ prostate weight, ↓ incidence and 
multiplicity of PCa lesions. 
Zhou  
2003 (37) 
5g/kg soy 
phytochemical 
concentrate 
SCID mice 
orthotopically 
implanted with 
LNCaP cells 
↓ tumorigenicity, ↓ lymph node 
metastasis, ↓ tumor weight,  ↓ 
proliferation, ↓  microvessel density 
Zhou  
2002 (34) 
0.5% soy 
phytochemical 
concentrate 
SCID mice 
orthotopically 
implanted with 
LNCaP cells 
↓ tumor weight, ↓incidence and 
multiplicity of lymph node and lung 
metastases, ↓ angiogenesis, ↑apoptosis  
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Absorption and Metabolism of Tomato Carotenoids and Soy Isoflavones 
 Carotenoid Absorption and Metabolism 
After release from the food matrix, carotenoids are incorporated into mixed micelles and 
absorbed into the enterocyte by simple diffusion or protein-mediated uptake by cholesterol 
transporters (53).  Several proteins involved in lipid transport may also be involved in carotenoid 
uptake into the enterocyte, including scavenger receptor class B type I (SR-BI), cluster 
determinant 36 (CD36), and Niemann Pick C1-like 1 (NPC1L1) (54). In the enterocyte, 
provitamin A carotenoids can be centrally cleaved by carotene 15,15'-monooxygenase (CMOI) 
to form all-trans-retinal (55).  Another carotenoid cleavage enzyme, carotene-9',10'-
monooxygenase (CMO-II) is a mitochondrial enzyme that can eccentrically cleave β-carotene to 
β-apocarotenals (56), and in vivo and in vitro evidence indicate that it can cleave lycopene (57, 
58) into potentially bioactive apo-lycopenoids (59). Carotenoids are packaged into chylomicrons 
in the enterocyte and secreted into the lymph (53). Carotenoid uptake into tissues may occur 
through similar transporters involved in intestinal absorption of carotenoids, and can be further 
cleaved by carotenoid cleavage enzymes which are expressed in most tissues (55).  The type of 
food matrix, fiber, and the amount and type of fat ingested with a meal are just a few dietary 
factors that can impact carotenoid bioavailability (53). 
Isoflavone Absorption and Metabolism 
Isoflavones in foods exist as four chemical forms – aglycones, glycosides, 
acetylglycosides and malonylgycosides. In soy foods, isoflavones are primarily found as 
glycosides (daidzin, genistin, and glycitin) which are poorly absorbed and must be hydrolyzed in 
the intestine by β-glucosidases on the brush border membrane of the enterocyte or by bacterial β-
glucosidases (60).  Aglycones can enter the enterocyte via passive diffusion to be glycosylated, 
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sulfated, or glucuronidated (60). In the liver, conjugated isoflavones go through first pass 
metabolism to conjugates and can enter systemic circulation or be excreted back into the 
intestine via the bile. In the intestine, isoflavones undergo deconjugation for reabsorption or are 
metabolized by the intestinal microbiota (60). Isoflavone absorption, metabolism and potential 
bioactivity are highly dependent on intestinal microbiota. Genistein can be reduced by intestinal 
microbiota to dihydrogenistein and further metabolized to p-ethyl phenol or 6’ – hydroxyl-o-
desmethylangolensin.  Low concentrations of glycitein metabolites have been detected in human 
urine and have been detected after in vitro fecal fermentation of glycitein (61, 62), but potential 
bioactivity of glycitein metabolites has not been investigated. Daidzein can be reduced to 
dihydrodaidzein and further metabolized to S-equol (7-hydroxy-3-(49-hydroxyphenyl)-chroman) 
or o-desmethylangolensin (ODMA).  It is estimated that only 30-40% of Caucasians and 40-60% 
of Asians can produce equol (63).  Equol is a bioactive metabolite and believed to be a 
significant contributor to the health benefits seen from soy consumption (64).  About 50% of 
equol in circulation is found in its unbound state and has a slow clearance rate (65); thus, its 
bioactivity is suspected to be even greater than the parent isoflavone, daidzein. Dose, dietary 
habits, food matrix and intestinal microbiota may impact isoflavone bioavailability and potential 
bioactivity (63).  
Whole foods and combinations of foods for prostate cancer prevention 
As recently reviewed by Hanahan and Weinberg, several important biological 
characteristics are acquired during the development of cancer including: “sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, inducing angiogenesis, activating 
invasion and metastasis and enabling replicative immortality”(66). A multi-targeted approach in 
cancer treatment by combining chemotherapeutic drugs that work through different mechanisms 
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(combination therapy), has been shown to be more effective and safer than monotherapy (67, 
68). Combining foods that have different bioactives with different anti-carcinogenic properties 
can result in changes on several biological pathways involved in carcinogenesis. Therefore, 
combinations of foods can be a multi-targeted approach in cancer prevention and may be more 
protective due to the presence of multiple phytochemicals that may have additive or synergistic 
bioactivity (69-71).  
There is limited research on the interactions and protective effects by consumption of 
multiple foods. Potential interactions between combinations of foods are difficult to examine in 
epidemiological or in vitro studies. In a multi-ethnic case-control study, no significant interaction 
was identified between intake of orange-yellow vegetables and total legumes or cruciferous 
vegetables and total legumes on PCa risk (72). In vivo, the combination of tomato and broccoli 
was more effective in reducing prostate tumor growth in rats than when these vegetables were 
consumed individually (15). The combination of dietary soy and tea, but not soy or tea alone, 
was effective in reducing inflammation and the development of PCa in the Noble rat model (49).  
There is limited, but suggestive evidence that combinations of foods may be more protective 
than individual foods or bioactives.  
Combination of Tomato and Soy in PCa 
Due to the accumulating evidence supporting the anti-cancer properties of tomato or soy 
products, there has been interest in the efficacy of the combination of these foods or their 
bioactives for prevention of carcinogenesis. A tomato and soy rich diet in men with PCa was first 
investigated by Grainger et. al. in 2007 (73). Men with PCa were randomized to consume a 
tomato-rich diet providing 25mg lycopene/day with no soy components or a 40g soy protein 
supplement providing 80mg isoflavones a day with no tomato products for four weeks. After 
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four weeks, men consumed a combination of a tomato-rich diet and soy protein supplementation 
for an additional four weeks. The authors noted high compliance of the dietary interventions in 
this population and no evidence of toxicity or significant adverse events. Over the eight week 
intervention, serum VEGF significantly declined and a trend of reduced PSA doubling time was 
identified. Although the trial was not long enough to evaluate cancer outcomes, this study was 
the first to evaluate compliance, safety and potential efficacy of a diet rich in both tomato and 
soy in men with PCa.  In men with hormone refractory PCa, lycopene supplementation was more 
effective at reducing the rate of increase in PSA than the combined supplementation of lycopene 
and soy isoflavones, proposing a negative interaction between lycopene and soy isoflavones (74). 
However, with no control group or soy isoflavone group, it is difficult to determine if there was 
truly a negative interaction. In men with a history of PCa and rising PSA, a ten week intervention 
with a dietary supplement containing soy isoflavones, lycopene, silymarin and other antoxidants 
resulted in a 2.6-fold decrease in PSA doubling time compared to the placebo group (75). 
Although the supplement contained bioactives other than soy isoflavones and lycopene, these 
results suggest that a combination of multiple bioactive compounds and food components is safe 
and potentially protective in men at high risk for PCa recurrence (75).  The safety and 
compliance of an intervention with a soy germ-fortified tomato juice for cancer prevention trials 
has recently been investigated in healthy adults (76). An eight week intervention with the juice 
significantly increased plasma lycopene and urinary isoflavone excretion and significantly 
lowered Cu 
+2
 mediated LDL+VLDL-C oxidation; thus, the bioactives in a tomato-soy juice are 
bioavailable and can function as antioxidants in vivo (76). The combination of lycopene and 
genistein was significantly more protective than lycopene or genistein alone at reducing tumor 
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volume in a rat model of breast cancer (77). The combination of tomato and soy for prevention 
of PCa has never been studied in an animal model. 
Progression and Metastasis of Prostate Cancer 
Screenings by annual digital rectal exams and serum PSA have increased the ability to 
detect PCa in its earlier stages. Due to earlier detection and the slow progression of PCa, recent 
recommendations for the treatment of localized cancers includes “watchful waiting” or active 
surveillance in an attempt to avoid costly, unnecessary treatments and the associated adverse side 
effects (78). PCa patients are monitored, and if the cancer appears to be progressing, treatments 
such as radical prostatectomy, hormonal ablation therapy, or radiation therapy are initiated. The 
progression of a localized PCa to a hormone-refractory, metastatic cancer may take decades, 
with men often dying with PCa, rather than from PCa.  In fact, autopsy studies estimate that over 
75% of men over the age of 85 have histological PCa (4).  The five-year survival rate for 
localized and regional PCa is 100%; however, once the PCa metastasizes, primarily to lymph 
nodes, bone, lung and liver, the five-year survival rate drops to less than 30% (1).  
The progression of primary PCa to metastasis is: primary tumor  local invasion (cells 
invade surrounding tissues)  intravasation (cells intravasate into a blood vessel to enter 
circulation  extravastion (cells exit blood vessel and invade a tissue)  macrometastasis 
(proliferation in a new site). The epithelial-to-mesenchymal transition (EMT) is suggested to 
contribute to the progression of primary PCa to metastatic disease.  EMT is characterized by 
changes in cellular morphology, cell-cell adhesion, tissue and cellular architecture, and 
acquisition of migratory abilities (Table 1.3) (79). Although EMT is a normal process involved 
in embryonic development and wound healing, acquisition of EMT in carcinogenesis facilitates 
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the ability of cancerous epithelial cells to invade and migrate across the basement membrane, 
resulting in metastasis (79).   
Table 1.3. EMT Markers in Prostate Carcinogenesis 
Gain of Mesenchymal Proteins Loss of Epithelial Proteins 
Cell Adhesion Proteins 
 N-cadherin 
 Integrins 
Cytoskeletal Proteins 
 Vimentin 
 Nuclear β-catenin 
Extracellular Matrix Proteins 
 Fibronectin 
 Laminin 
 Collagens 
Matrix Metalloproteinases  
 MMP-2 
 MMP-3 
 MMP-9 
Transcription Factors that Induce EMT 
 Snail 
 Slug 
 Twist 
 ZEB1 
 
Cell Adhesion Proteins 
 E-cadherin 
 Desmoplakin 
 Cytokeratin 
 Occludin 
 
 
 
 
 
 
 
 
E-cadherin is a glycoprotein that mediates homotypic cell-cell adhesion in epithelial cells 
and is essential in the maintenance of the architecture of epithelium. E-cadherin is linked to the 
cytoskeleton via β-catenin; thus, loss of expression in EMT not only results in reduced cell 
adhesion, but also frees β-catenin to enter the nucleus and induce expression of EMT-related 
genes (80).  Integrins, heterodimeric adhesion receptors, facilitate the relocation of cells by 
binding to ligands in the extracellular matrix including fibronectin, collagens, and laminins (80).  
EMT is also characterized by increased expression of matrix metalloproteinases (MMP), 
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endopeptidases that degrade the basement membrane and extracellular matrix, facilitating 
invasion and the release of growth factors from the stroma that can enhance tumor growth (81). 
Decreased E-cadherin expression in primary PCa has been correlated with advanced 
Gleason score, advanced tumor stage and grade, shorter overall survival and presence of 
metastases (82).  Increased expression of vimentin correlated with biochemical recurrence and 
bone metastases, and ZEB1, TWIST, MMPs and N-cadherin expression in PCa have all been 
associated with advanced Gleason score (82, 83). Interestingly, the combination of low E-
cadherin and high N-cadherin expression in PCa, indicative of the “cadherin switch”, a hallmark 
of EMT, was significantly and strongly associated with biochemical failure, clinical recurrence, 
locoregional recurrence, skeletal metastases and cancer-specific survival (84). Thus, expression 
of EMT-related markers, particularly reduced E-cadherin and increased N-cadherin expression, 
has been identified in clinical PCa samples and may be an indicator of increased risk of 
metastasis and poor prognosis.   
Broccoli Consumption for Prevention of Prostate Cancer Progression 
The long latency period between PCa diagnosis and potential metastasis provides an ideal 
therapeutic window for dietary interventions to prevent progression to metastatic disease.  There 
is some epidemiological and laboratory evidence to suggest that broccoli consumption may 
prevent progression of existing PCa and reduce the risk of advanced PCa.  Consumption of more 
than one serving of broccoli a week was associated with a reduced risk of aggressive and 
extraprostatic PCa in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (85), 
and in a multi-ethnic population, consumption of cruciferous vegetables, such as broccoli, was 
associated with a reduced risk of advanced PCa (72).  Not only may broccoli consumption 
reduce the initial risk of being diagnosed with an aggressive PCa, broccoli consumption post-
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diagnosis could prevent the progression of existing PCa.  Post-PCa diagnosis, men in the highest 
quartile of cruciferous vegetable intake (median intake = 0.92 servings/day) had a nearly 60% 
reduced risk of cancer progression (86).   A 12-month broccoli rich diet in men with high-grade 
PIN, a precancerous stage of neoplasia, modulated mRNA expression of genes involved in TGF-
β, EGF and insulin signaling pathways known to be associated with carcinogenesis (87).  
In vitro and in vivo, bioactives in broccoli, such as indole-3-carbinol (I3C) and 
sulfurophane, have prevented migration and metastasis of PCa. In vitro, I3C inhibited the 
migration of PCa cells by increasing phosphorylation of β-catenin for subsequent degradation 
(88). I3C, via i.p. or i.v. injections, inhibited incidence of lung metastases and significantly 
increased survival in the MAT-LyLu rodent model of PCa (89).  In TRAMP mice, sulfurophane 
reduced the incidence of pulmonary metastasis (90), and a follow-up in vitro study found that 
this may have been due to sulfurophane’s ability to inhibit PCa cell migration (91). Clinical trials 
to evaluate the safety and efficacy of interventions with diindolylmethane (a metabolite of I3C) 
brassica vegetables, or I3C for prevention of PCa progression have been completed (92), and it 
will be of interest to learn if in vitro and in vivo evidence translates to clinically significant 
reductions in progression of PCa.   
Transgenic adenocarcinoma of the mouse prostate (TRAMP) model  
Serum PSA is often used as a biomarker in clinical trials, but it may not be sensitive 
enough to measure the efficacy of dietary interventions (93). Without long term dietary 
intervention trials that include more sensitive cancer biomarkers or measures of cancer 
incidence, it is difficult to truly examine the efficacy of foods identified as protective from 
epidemiological trials (93).  Animal models are extremely valuable in evaluating safety and 
efficacy of an intervention, and the TRAMP model has provided much utility for evaluating the 
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efficacy of dietary interventions. Dietary compounds such as genistein, tocopherols, and tea 
polyphenols have been identified as potential chemopreventive compounds through use of this 
model (94). All TRAMP mice develop prostatic intraepithelial neoplasia, which progresses 
through all stages of carcinogenesis and eventually metastasizes due to androgen-driven and 
prostate-epithelium specific expression of SV40 T antigens. SV40 T antigen is expressed 
downstream of the prostate-specific rat probasin promoter and suppresses the function of tumor 
suppressors Rb and p53, resulting in a prostate-specific cancer that closely mirrors the human 
pathogenesis of PCa (95). The most common endpoint in the TRAMP model is histpathology for 
evaluation of cancer incidence and severity; prostate weight, metastasis incidence and survival 
are also common endpoints. 
Aims of Dissertation 
There is a growing body of scientific evidence identifying potential bioactive compounds 
and anti-carcinogenic properties of fruits and vegetables. However, there is limited research as to 
how whole foods and combinations of foods may reduce the incidence of PCa.  PCa is diagnosed 
later in life and the long latency period between PCa diagnosis and potential metastasis provides 
an ideal therapeutic window for dietary interventions to prevent progression to metastatic 
disease.  The overall hypothesis of this project is that dietary interventions with whole foods and 
combinations of foods can reduce the incidence and progression of PCa.  The specific aims of 
this work are to: 
1) Determine bioavailability of tomato carotenoids and soy germ isoflavones when 
tomato and soy germ are consumed together 
2) Examine the efficacy of consumption of tomato powder or soy germ, alone and in 
combination, for prevention of prostate carcinogenesis 
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3) Determine if broccoli containing diets can inhibit the epithelial to mesenchymal 
transition in prostate cancer. 
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CHAPTER 2 
COMBINED CONSUMPTION OF SOY GERM AND TOMATO POWDERS RESULTS 
IN ALTERED ISOFLAVONE AND CAROTENOID BIOAVAILABILITY IN RATS 
1,2
 
 
ABSTRACT 
The efficacy of combinations of foods for enhanced anticancer activity is of clinical interest, but 
there is limited information on the effect of combined consumption on bioactive bioavailability. 
Male Copenhagen rats consumed diets containing 10% tomato powder (TP), 2% soy germ (SG), 
neither, or a combination (TP+SG) for 25 weeks (n=63) or 7 days (n=24). After 7 days, serum 
carotenoids were significantly lower after TP+SG feeding compared to TP alone. After 25 
weeks, the TP+SG group had significantly lower lycopene and β-carotene concentration in the 
testes, seminal vesicles, and ventral prostate compared to the TP group and significantly higher 
urinary isoflavone excretion compared to the SG group. Differences in carotenoid 
bioaccumulation were not explained by mRNA expression of scavenger receptor class B type I, 
carotene 15,15’-monooxygenase I, carotene 9’,10’-monooxygenase II in the liver, prostate or 
duodenal mucosa. Differences in urinary isoflavone excretion were not explained by activity of 
hepatic detoxification enzymes. The results suggest interactions between soy germ and tomato 
powder that enhance isoflavone absorption but reduce carotenoid bioavailability.  
 
1 Reprinted with permission from Zuniga KE, Erdman JW,Jr. J Agric Food Chem. 
2011;59(10):5335-41. Copyright 2011 American Chemical Society 
2 Additional tables and figures not included in the published manuscript are in Appendix A. 
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INTRODUCTION 
A diet containing a variety of fruits and vegetables is recommended to reduce the risk of 
chronic disease. Numerous foods and bioactive compounds have shown chemopreventive 
potential against prostate cancer (PCa) (1), the most diagnosed cancer in U.S. men (2).  A 
growing body of evidence suggests that consumption of soy or tomato products is associated 
with a reduced risk of PCa (3, 4).  Soy is a rich source of bioactives including isoflavones, 
saponins, and lignans. Research suggests soy isoflavones may inhibit proliferation, increase 
apoptosis, inhibit tumor growth and angiogenesis, be anti-inflammatory, and modulate steroid 
hormone levels and receptors in the prostate (5). Tomatoes are also of interest for the prevention 
of PCa due to the anticarcinogenic properties of their nutrients and phytochemicals, primarily 
polyphenols and carotenoids such as lycopene, phytoene, phytofluene, and β-carotene (6). 
Tomato phytochemicals have been suggested to induce cell-cycle arrest, induce phase II 
enzymes, function as antioxidants, modulate growth factor signaling, and increase cell-cell 
communication via gap junctions (6, 7). Typically, tomato and soy products are not consumed 
together; however, the use of combinations of these foods and their bioactives has gained interest 
for the prevention of PCa (8, 9). Whole foods and combinations of foods and bioactives may be 
more protective due to the presence of multiple phytochemicals that may have additive or 
synergistic bioactivity (10-12); however, not all combinations of foods or bioactives will be 
beneficial. PCa patients with rising prostate-specific antigen (PSA) were randomized to receive 
supplements containing 15 mg of lycopene or 15 mg of lycopene plus 40 mg of soy isoflavones 
twice daily for 6 months. Lycopene supplementation was more effective in reducing serum PSA 
progression than the combined supplementation, suggesting a negative interaction between 
lycopene and soy isoflavones (9). 
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The efficacy of combinations of foods and bioactives for enhanced health benefits is of 
clinical interest, but there is limited information on the interactions between foods that affect 
bioavailability or bioactivity of phytochemicals. The purpose of this study was to measure the 
bioavailability of soy germ isoflavones and tomato carotenoids in male Copenhagen rats after 
individual and combined consumption of soy germ and tomato powder. Exposure to bioactives 
was estimated by carotenoid bioaccumulation and urinary isoflavones. The effects of diet on the 
expression of scavenger receptor class B type I (SR-BI) (a protein involved in carotenoid 
absorption13) and the carotenoid metabolizing enzymes carotenoid 15,15’-monooxygenase 
(CMOI) and carotenoid 9’,10’-monooxygenase II (CMOII) were measured in the prostate, liver, 
and duodenal mucosa. 
MATERIALS AND METHODS 
Animals and Experimental Design. The University of Illinois Laboratory Animal Care 
Advisory Committee approved all animal procedures. 
Short-Term Feeding. Twenty-four male Copenhagen rats (Cop 2331; Harlan, 
Indianapolis, IN) were acquired at ∼34 weeks of age, housed individually in wire-bottom cages, 
and acclimated to powdered AIN-93G diet for 1 week. Animals were then randomized (n= 
6/group) to consume AIN-93G-based experimental diets for 7 days. Experimental diets were 
AIN-93G control, 10% whole tomato powder (FutureCeuticals, Momence, IL), 2% soy germ 
powder (Frutarom, North Bergen, NJ), and 10% tomato powder with 2% soy germ powder. 
Soygerm, the hypocotelydon of soy, is separated during milling of whole soybeans and is a 
concentrated source of soy bioactives including isoflavones, saponins, and phytosterols. Soy 
germ has a unique isoflavone profile with about 59% daidzein, 34% glycitein, and 7% genistein. 
In contrast, the typical isoflavone profile of soy products that utilize the whole soybean is 
35 
 
approximately 40% daidzein, 10% glycitein, and 50% genistein. Diets were balanced for protein, 
fat, energy, and fiber, and stored at 4°C in the dark (Table 2.1). Diets were made with cottonseed 
oil rather than soybean oil to minimize exogenous isoflavones. Rats were weighed weekly, and 
individual feed intake was measured every 48 h when fresh diet was provided. 
Long-Term Feeding. Sixty-three male Copenhagen rats (COP/NCrl; Charles River, 
Wilmington, MA) were obtained at ∼6 weeks of age and individually housed in wire-bottom 
cages. After 1 week of adaptation to powdered AIN-93G diet, animals were randomly assigned 
to consume AIN-93G control (n=17), 10% whole tomato powder (n=17), 2% soy germ powder 
(n=16), or 10% tomato powder with 2% soy germ powder (n=13) for 25 weeks. Due to seasonal 
and batch variations, the carotenoid content of the tomato powders differed between the long-
term and short-term studies (Table 2.1). 
Carotenoid Extraction and Quantification. Carotenoid extraction was performed using 
previously published techniques described by our laboratory (13, 14). General precautions for 
work with carotenoids were taken throughout the extraction procedure. Briefly, 5mL of ethanol 
solution containing 0.01% BHT was added to tissue or 25 mg of diet. Adrenals, ventral prostate, 
seminal vesicles, and testes were pooled within groups to facilitate HPLC detection of 
carotenoids, and liver and serum were extracted in duplicate. Tissues were minced thoroughly, 
and diet was homogenized for 75 s. Samples were saponified with 1 mL of saturated KOH for 30 
min at 60 °C. Diet and tissue samples were extracted three times with 6 mL of hexane. Three 
hundred microliters of an ethanol/BHT solution was added to 300 μL of serum and extracted 
three times with 1.5 mL of hexane.  Extracts were dried in a Speedvac (model AS160; Savant, 
Farmingdale, NY) evaporator, flushed with argon, and stored at -20 °C for 48 h before reverse-
phase HPLC-PDA analysis as previously described (14). Analytical standards of lycopene, 
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phytoene, phytofluene, and β-carotene were used for quantification. An analytical standard for 
lycopene was extracted from Redvivo 10% lycopene beadlets (gift from DSM Nutritional 
Products, Kaiseraugst, Switzerland), and phytoene, phytofluene, and β-carotene analytical 
standards were gifts from Hansgeorg Ernst from BASF (Ludwigshafen, Germany). Our 
laboratory participates in the National Institute of Standards and Technology Fat Soluble 
Vitamin Round Robin Program, and our lycopene analysis is consistently within one standard 
deviation of the Round Robin median/expected value. 
Urinary Isoflavone Quantification. In the short -term feeding, 24-48 h before study 
termination, rats were randomized to metabolic cages for a 24 h urine collection. Urine was 
hydrolyzed with β-glucuronidase (from Escherichia coli K12, 200 U/mL at 25 °C; Roche 
Diagnostics, Indianapolis, IN) and arylsulfatase (from Helix pomatia 24190 U/g; 2 mg/mL in 1M 
(pH 6.0) acetate buffer; type H-1, Sigma, St. Louis, MO) for 1 h at 37 °C. Incubates were 
extracted with 1.5 mL of methyl tert-butyl ether and evaporated to dryness. During the final 
week of feeding in the long-term study, rats were randomized to metabolic cages for 24-h urine 
collection. Urine was hydrolyzed with β-glucuronidase and sulfatase (from H. pomatia; 500 
U/mL in 1 M (pH 5.0) acetate buffer; type H-1, Sigma) for 16 h at 37 °C. Incubates were 
extracted three times with 2 mL of diethyl ether and evaporated to dryness. In both studies, 
13
C3-
daidzein, equol, O-desmethylangolensin (DMA), and 
2
H4-genistein (provided by Cancer 
Research Center of Hawaii) were added as internal standards, and extracted samples were 
resuspended in 1:1 methanol/0.1% aqueous formic acid and analyzed for genistein, daidzein, 
glycitein, and equol by LC-MS as previously described (15) at the Cancer Research Center of 
Hawaii analytical laboratory. 
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Isolation of Hepatic Microsomal and Cytosolic Fractions. A 300 mg sample of liver 
was homogenized in 1 mL of 0.05MTris-HCl buffer (pH 7.4) and centrifuged at 10,000 x g for 
20 min at 4 °C. The microsomal and cytosolic fractions were separated by centrifugation of the 
supernatant at 10,000 x g for 60 min at 4 °C. The microsomal fraction was resuspended in 1 mL 
of 0.05 M Tris-HCl buffer (pH 7.4) with 0.25 M sucrose. Both fractions were snap frozen in 
liquid nitrogen and stored at -80°C until further use. 
Enzyme Activity. Cytochrome P450 1A (CYP1A) activity in the microsomal fraction 
and NQO1 activity in the cytosolic fraction were measured as previously described (13).  Briefly, 
the formation of resorufin from ethoxyresorufin by ethoxyresorufin O-deethylase (EROD) was 
measured in an FLx800 plate reader (BioTek Instruments, Winooski,VT) over 3 min and 
calculated using a resorufin standard curve. CYP1A activity is correlated with EROD activity; 
therefore, the specific activity of CYP1A was calculated as picomoles of resorufin per minute 
per milligram of protein. NAD(P)H-quionone oxidoreductase 1 (NQO1) in the cytosolic fraction 
was measured as nanomoles of MTT reduced per minute per milligram of protein. In the reaction 
mixture, NQO1 reduces menadione to menadiol, and the amount of MTT reduced by menadiol 
(colorimetric assay) was quantified in a microplate absorbance reader. 
Real Time Quantitative PCR. At time of tissue harvest, duodenal mucosa, dorsolateral 
prostate, and a section of liver was placed in RNAlater solution (Ambion, Austin, TX) and stored 
at 4°C for 24 h. Tissues were then blotted dry and transferred to a fresh tube for storage at -80°C 
until analysis. RNA was extracted from tissues with Trizol (Invitrogen, Carlsbad, CA), DNase 
treated (New England Biolabs, Ipswich, MA), and synthesized into cDNA by a High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). mRNA expression of 
carotenoid 15,15’-monooxygenase I (NM_053648), forward 5ʹ-
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CCTAGAGCTCCCTCGGATAAATTA and reverse 5ʹ-GTTGGGACTGGACTCCATTGTACT-
3ʹ; carotenoid 9ʹ,10ʹ-monooxygenase II (DQ083174), forward 5ʹ-
ACCATCTCCCAGTTTTGAAGAAC-3ʹ and reverse 5ʹGCAATGCACGGCAGACTCT-3ʹ; SR-
BI (NM_01541.1), forward 5ʹ-CTGGTGCCCATCATTTACCAA-3ʹ and reverse 5ʹ-
AGCCCTTTTTACTACCACTCCAAA-3ʹ; and ribosomal protein L7a (RPL7a, 
NM_001114391) forward 5ʹ-GAGGCCAAAAAGGTGGTCAATCC-3ʹ and reverse 5ʹ-
CCTGCCCAATGCCGAAGTTCT-3ʹ was measured by real-time PCR using SYBR Green 
Master Mix (Applied Biosystems, Foster City, CA) and monitored by an ABI Prism 7900HT 
(Applied Biosystems). RPL7a was used as a housekeeping gene, and relative mRNA abundance 
was determined using the comparative critical threshold method. 
Hepatic Lipid Content and Serum Cholesterol. Serum total cholesterol was measured 
in duplicate with a diagnostic Cholesterol E Kit (Wako Chemicals, Richmond, VA). Liver lipids 
were extracted in duplicate using a modified Folch method as previously described (16). 
Statistical Analysis. Data are shown as the mean ±SEM. Differences in carotenoid 
concentration and urinary isoflavones were analyzed by a Student t-test and considered to be 
significant at p<0.05. Differences among treatment groups for weight, feed intake, and gain/feed 
ratio were analyzed by one-way analysis of variance (ANOVA) followed by post hoc Tukey-
Kramers studentized range test with α < 0.05 when the assumptions of ANOVA were met; 
otherwise, the Wilcoxon and Kruskal-Wallis nonparametric tests were used. Differences among 
treatment groups for mRNA expression, hepatic lipids, serum cholesterol, and enzyme activity 
were analyzed by one-way ANOVA followed by orthogonal contrast tests for a priori 
hypotheses. All statistical analyses were conducted with SAS (version 9.2; SAS Institute, Cary, 
NC). 
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RESULTS AND DISCUSSION 
Weight Gain and Feed Intake. All diets were readily consumed, and there were no 
differences in feed intake between diet groups in either the long-term or short-term studies 
(Table 2.2).  However, in the long-term study, the TP+SG group gained significantly less weight 
than the TP group, and the gain/feed ratios of the SG and TP+SG groups were significantly 
lower than that of the TP group. All diets were isocaloric and matched in macronutrients; 
therefore, the differences in weight gain were unexpected. Previous rodent studies have shown 
significant effects on weight gain and fat mass by dietary supplementation with soy or its 
phytoestrogens, suggesting that soy or its bioactives may alter metabolism by increasing energy 
expenditure and activating fatty acid oxidation (17).  The metabolic effects of dietary soy germ 
in rats have never been investigated, and the reduced weight gain by long-term feeding of soy 
germ suggests that the experimental diets contained enough soy isoflavones to modulate energy 
utilization compared to the tomato powder group. 
Serum and Tissue Carotenoids. In the short-term study, the TP+SG group had 
significantly lower serum levels of phytoene (-42%, p=0.01), phytofluene (-77%, p<0.001), and 
lycopene (-56%, p=0.02) than the TP group (Figure 2.1), which suggests that soy germ may alter 
the initial absorption and/or metabolism of carotenoids (Table A.1). Long-term consumption of 
TP+SG did not result in a significant reduction in serum carotenoids compared to the TP group 
(Table 2.3); however, there was a general reduction in carotenoid bioaccumulation in rats fed 
TP+SG compared to TP alone. Lycopene and β-carotene concentrations in the testes (p=0.001, 
p=0.003), seminal vesicles (p=0.04, p=0.003), and ventral prostate (p=0.002, p=0.001), 
respectively were significantly lower in the TP+SG group than in the TP group. 
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Carotenoid saturation of lipoproteins in the 25-week feeding, but not in the 7-day study, 
may explain why there were no significant differences in serum carotenoids between the TP and 
TP+SG groups in the 25-week study. Carotenoids are transported in the blood by lipoproteins, 
and studies suggest that serum carotenoid concentrations eventually plateau. A previous rat study 
in our laboratory showed that serum lycopene levels were not significantly different between 
animals receiving dietary lycopene supplementation of 0.05 or 0.50 g/kg diet after 8 weeks (18), 
suggesting a saturation point in the blood. In men with prostate cancer, lycopene 
supplementation resulted in increased plasma lycopene levels that reached a plateau at 3 months 
and remained stable for the duration of the 12-month intervention (19).  Differences in tissue 
carotenoids but not serum carotenoids in the long-term study suggest that in long-term 
consumption, serum carotenoids may reach a plateau and may not be an accurate indicator of 
tissue carotenoid bioavailability. 
CMOI, CMOII, and SR-BI mRNA Expression. The differences in tissue carotenoid 
bioaccumulation in the long-term feeding suggest that soy germ may alter carotenoid uptake 
and/or metabolism. Carotenoid 15,15’-monooxygenase (CMOI) centrally cleaves provitamin A 
carotenoids to retinal. Carotenoid 9’,10’-monooxygenase II (CMOII) can eccentrically cleave β-
carotene to β-apocarotenals (20), and in vivo and in vitro evidence suggests that it may cleave 
lycopene (21, 22). Compared to the control group, hepatic CMOI expression was significantly 
higher in rats consuming 10% tomato powder for 25 weeks, but there was no up-regulation in the 
TP+SG group (Table 2.4), suggesting potential differences in bioactivity of these dietary 
interventions. There were no other alterations by diet in CMOI or CMOII expression in the liver, 
duodenal mucosa, or dorsolateral prostate. In vitro studies suggest that dietary flavonoids, such 
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as the soy isoflavone genistein, may alter CMOI activity (23); therefore, potential changes in 
enzyme activities by soy germ are of further interest. 
Carotenoids must be incorporated into mixed micelles composed of bile salts and dietary 
lipids before absorption into the enterocyte and subsequent secretion into the lymph via 
chylomicrons (24). Absorption into the enterocyte may be through simple diffusion or receptor-
mediated transport such as through scavenger receptor, class B, type I (SR-BI) (24). The 
expression of SR-BI was measured but was not significantly altered by diet in duodenal mucosa, 
liver, or dorsolateral prostate, suggesting that differences in carotenoid bioaccumulation were not 
through differences in carotenoid transport. However, carotenoids may also be absorbed by 
passive diffusion or other transporters (25), which were not measured. 
Hepatic Lipids and Serum Cholesterol. Due to the lipophilic nature of carotenoids, the 
absorption and subsequent bioavailability are dependent on factors that may affect 
micellerization of carotenoids such as the amount of dietary fat in the meal or the presence of 
sterols, stanols, or fiber (24). Soy germ diets contained 1 mg/kg sterols and stanols (analysis 
provided by supplier), and reduced carotenoid absorption by sterols and stanols has also been 
correlated with reduced LDL cholesterol levels (24). There were no significant differences in 
total hepatic lipid accumulation (36.2 ± 5.2 mg/g tissue) or total serum cholesterol (160.0 ± 22.2 
mg/dL) between any of the groups (Table A.2), suggesting that differences in carotenoid 
bioaccumulation by dietary soy germ were not likely due to effects on intestinal micellerization 
or lipid absorption. A limitation of the study is that only total serum cholesterol was measured; 
therefore, dietary influences on individual lipoproteins were not able to be identified. 
Urinary Soy Isoflavones. Isoflavones in foods exist primarily as glycosides and must be 
hydrolyzed by β-glucosidases on the brush border membrane or by bacterial β-glucosidases in 
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the intestine before absorption. Aglycones can then enter the enterocyte via passive diffusion to 
be glycosylated, sulfated, or glucuronidated (26). In the liver, conjugated isoflavones go through 
first-pass metabolism and can be excreted back into the intestine via the bile. In the intestine, 
isoflavones undergo deconjugation for reabsorption or undergo further metabolism by the 
intestinal microflora to form metabolites such as O-desmethylangolensin and equol (25).  
Isoflavone absorption and metabolism are highly dependent on intestinal microflora, but other 
factors such as dose, dietary habits, and the food matrix may affect bioavailability (27). In the 
short-term study, urinary excretion of glycitein was significantly higher in the SG group than in 
the TP+SG group, but there were no other significant differences between groups (Table 2.5). In 
the long-term study, urinary total isoflavones, daidzein and equol, were significantly higher in 
the TP+SG group than in the SG group. Feed intakes between diet groups were not significantly 
different; therefore, the data suggest that long-term consumption of tomato powder may enhance 
isoflavone absorption and/or equol production. 
Hepatic Detoxification Enzyme Activity. The isoflavones daidzein, genistein, and 
glycitein are known substrates of CYP enzymes (28, 29); therefore, we hypothesized that the 
different urinary isoflavone profiles between the SG and TP+SG groups may be explained by 
differences in hepatic metabolism by phase I and II enzymes. However, diet had no effect on 
hepatic NQO1 enzyme activity in the long-term or short-term studies (Tables A.3 and A.4), and 
hepatic EROD activity was not altered by diet in the long-term study (Tables A.3 and A.4).  In 
the short-term study, hepatic EROD activity was 1.6 times higher in rats that consumed TP+SG 
compared to SG alone (p<0.01). Higher hepatic EROD activity in the TP+SG group may 
indicate increased isoflavone metabolism, partially explaining the general trend of lower urinary 
isoflavone excretion compared to the SG group in the short-term feeding.  
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A possible explanation for the increase in urinary isoflavones after long-term 
consumption of TP+SG may be increased isoflavone absorption in the gut facilitated by gut 
microflora. Diets high in fiber have been suggested to increase production of equol (30, 31) and 
dietary factors, including fiber, may alter intestinal transit time or change the composition of 
intestinal microflora to increase deconjugation of isoflavones for absorption and metabolism 
(32). Cellulose, an insoluble fiber, is the fiber source in AIN-93G diets, and in our experimental 
diets, the amount of cellulose was adjusted to account for the fiber provided by tomato powder 
and/or soy germ in those respective diets. Although diets in this study were adjusted to contain 
equal amounts of fiber, tomato powder containing diets would have had more soluble, 
fermentable fiber that could support the intestinal microflora that metabolize isoflavones. The 
positive interaction between tomato and soy on isoflavone bioavailability may also depend on 
the type of tomato or soy product consumed. Men with recurring prostate cancer who consumed 
a soy protein supplement in combination with a tomato-rich diet for 4 weeks had significantly 
lower urinary isoflavones than when they consumed just the soy protein supplement (8). Men on 
the tomato-rich diet primarily consumed tomato juice (∼11 servings/week), which is low in 
fiber, rather than raw tomatoes (∼4 servings/week) (8), which may explain why consumption of 
tomato powder, a source of fiber, may have increased urinary isoflavones in rats but not in men 
consuming tomato juice. 
Increased bioavailability of isoflavones in the long-term TP+SG group could be partially 
explained by the activity of tomato polyphenols (quercetin and kaempferol). In mice, the 
bioavailability of the isoflavone biochanin A was increased by coadministration of the 
polyphenols quercetin and epigallocatechin-3-gallate as indicated by increased plasma 
concentration and urinary excretion of biochanin A (33). Investigation into the possible 
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mechanism suggested that polyphenols may inhibit efflux transporter mediated elimination of 
biochanin A and increase the amount of the more bioavailable aglycone by competing for 
glucuronidation/sulfation in the intestine (33). Our results suggest that long-term consumption of 
tomato powder polyphenols may have had a similar interaction with soy isoflavones, resulting in 
increased urinary isoflavones. 
 Utilization of a combination of foods and bioactives is gaining interest in the prevention 
of chronic disease. Whole foods are a complex matrix composed of a mixture of nutrients and 
bioactives, and it should not be assumed that all combinations of functional foods will be more 
effective. Results from this study emphasize the importance of preclinical trials to ensure 
bioavailability of the bioactives of interest and potential interactions between functional foods 
that could alter the efficacy or safety of dietary interventions. 
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FIGURES AND TABLES 
 
Table 2.1. Composition of experimental diets 
g/100g  total diet 
 Control 
10% Tomato 
Powder 
a
 
2% Soy 
Germ 
b
 
10% Tomato Powder + 2% 
Soy Germ 
ab
 
Cornstarch 39.7 35.2 39.7 35.2 
Casein 20.0 18.5 19.1 17.6 
Maltodextrin 13.2 11.8 13.2 11.8 
Sucrose 10.0 10.0 10.0 10.0 
Fiber 
c
 5.0 3.3 4.4 2.7 
Mineral Mix
 d
 3.5 3.5 3.5 3.5 
Vitamin Mix 
e
 1.0 1.0 1.0 1.0 
L-Cystine 0.3 0.3 0.3 0.3 
Choline Bitrate 0.3 0.3 0.3 0.3 
Cottonseed Oil 7.0 6.5 6.6 6.2 
Tomato Powder
 f
  10.0  10.0 
Soy Germ
 g
     2.0 2.0 
a 
Short-term study diet contains 41 nmol lycopene, 0.9 nmol β-carotene, 11.9 nmol phytoene, and 
3.7 nmol phytofluene per gram of diet. Long-term study diet contains 149 nmol lycopene, 1.5 
nmol β-carotene, 6.4 nmol phytoene, and 1.8 nmol phytofluene per gram of diet. 
b 
Contains 670 nmol total daidzein, 387 nmol total glycitein, and 74 nmol total genistein per 
gram of diet.  
c
 Non-nutritive cellulose, 
d
 AIN93-MX formulation, 
e
 AIN93-VX formulation 
f 
 FutureCeuticals ‘HiActives’ Tomato Powder 2000 N8 
g
  Frutarom SoyLife® Complex Micro  
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Table 2.2. Body weight and feed intake in 7-day and 25-week feeding studies 
Diet AIN-93G 10% Tomato 
Powder 
2% Soy Germ 10% Tomato 
Powder + 2% 
Soy Germ 
7-Day Feeding Study 
Starting Weight (g) 366 ± 12  366 ± 10 367 ± 10   360 ± 11 
Ending Weight (g)  383 ± 11  381 ± 12 382 ± 10 378 ± 8 
Total Feed Intake (g)       152 ± 4.0          140 ± 7.0      138 ± 3.0 150 ± 9 
Gain:Feed (g/g)   0.11 ± 0.02   0.10 ± 0.02   0.11 ± 0.01     0.11 ± 0.02 
25-Week Feeding Study 
Starting Weight (g) 159 ± 2 160 ± 2 161 ± 2 159 ± 3 
Ending Weight (g)    403 ± 6 
ab
   420 ± 6 
b
   399 ± 6 
a
   388 ± 6 
a
 
Total Feed Intake (g) 2740 ± 30 2740 ± 40 2790 ± 50 2710 ± 40 
Gain:Feed Ratio (g/g) 0.089 ± 0.002 
ab
 0.095 ± 0.002 
b
 0.085 ± 0.002 
a
 0.084 ± 0.001 
a
 
Values are means ± SEM.  
Different superscript letters within rows indicate significant difference between treatments 
(p<0.05). 
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Table 2.3 Serum and tissue carotenoid concentration in 25-week feeding 
Carotenoid 10% Tomato Powder 10% Tomato Powder + 2% Soy Germ 
                          Serum (nmol/L)  
Phytoene 262 ± 18 193 ± 29 
Phytofluene 113 ± 20 92 ± 17 
Lycopene 512 ± 96 479 ± 120 
β-carotene ND ND 
                        Liver (nmol/g)  
Phytoene 29.2 ± 1.8 
a
 19.5 ± 0.9 
b
 
Phytofluene 55.3 ± 6.4 
a
 36.1 ± 2.9 
b
 
Lycopene           141 ± 19                       103  ± 7.0 
β-carotene ND ND 
                             Adrenals (nmol/g)  
Phytoene 24.9 ± 3.2 18.4 ± 1.2 
Phytofluene 28.5 ± 4.0 19.6 ± 1.4 
Lycopene 19.8 ± 2.6 13.7 ± 0.8 
β-carotene     0.30 ± 0.03 a     0.19 ± 0.01 b 
                          Testes (nmol/g)  
Phytoene 0.06 ± 0.01 0.05 ± 0.01 
Phytofluene 0.19 ± 0.03 0.16 ± 0.02 
Lycopene   1.04 ± 0.07 
a
   0.59 ± 0.08 
b
 
β-carotene   0.010 ± 0.001 a   0.006 ± 0.001 b 
                           Seminal Vesicles (nmol/g)  
Phytoene ND ND 
Phytofluene 0.026 ± 0.001 
a
 0.018 ± 0.001 
b
 
Lycopene 0.22 ± 0.01 
a
 0.19 ± 0.01 
b
 
β-carotene 0.0038 ± 0.0001 a 0.0030 ± 0.0001 b 
                               Ventral Prostate (nmol/g)  
Phytoene ND ND 
Phytofluene 0.058 ± 0.003 
a
 0.043 ± 0.002 
b
 
Lycopene 0.53 ± 0.02 
a
 0.38 ± 0.01 
b
 
β-carotene  0.0095 ± 0.0003 a 0.0065 ± 0.0003 b 
Values are the mean ± SEM. Liver, serum, and testes, n=7; adrenals n=3; seminal vesicles, and 
ventral prostate n=3-4.  
Different superscript letters within a row indicate significant differences between treatments 
(p<0.05). 
ND = carotenoid levels below detection limit 
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Table 2.4. Hepatic, intestinal, and prostatic mRNA expression of CMOI, CMOII, and SR-BI in 
25-week feeding study  
 Fold Change 
 
 
Tissue 
AIN-93G 10% Tomato 
Powder 
2% Soy Germ 10% Tomato 
Powder + 2% 
Soy Germ 
                                 CMOI 
Liver 1.0 ± 0.1 
a
   1.9 ± 0.4 
b
   1.4 ± 0.1 
ab
    1.4 ± 0.1 
ab
 
Duodenal Mucosa     1.0 ± 0.3 1.1 ± 0.2      0.8 ± 0.2 0.7 ± 0.1 
Dorsolateral Prostate ND ND ND ND 
                                  CMOII 
Liver 1.0 ± 0.1 1.3 ± 0.3 1.1 ± 0.2 0.9 ± 0.1 
Duodenal Mucosa 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.2 0.9 ± 0.1 
Dorsolateral Prostate 1.0 ± 0.2 2.0 ± 0.9 0.9 ± 0.2 1.9 ± 0.9 
                                    SR-BI 
Liver 1.0 ± 0.2 1.5 ± 0.4 2.6 ± 0.9 2.1  ± 0.6 
Duodenal Mucosa 1.0 ± 0.2 1.3 ± 0.3 1.0 ± 0.2 0.8  ± 0.1 
Dorsolateral Prostate 1.0 ± 0.3 1.0 ± 0.3 0.8 ± 0.2 0.7  ± 0.1 
Values reported as relative to expression in controls (AIN-93G), which was set to 1. Results 
shown are the mean ± SEM, n=7-11.  
Different superscript letters within a row indicate significant differences between treatments 
(p<0.05).  
ND = expression was not detected.  
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Table 2.5. 24-Hour urinary isoflavone excretion in 7-day and 25-week feedings 
                µmol of isoflavone/L of urine 
 2% Soy Germ 10% Tomato Powder + 2% Soy Germ 
                       7-Day Feeding 
Daidzein 184 ± 23  131 ± 11  
Genistein 14 ± 2 12 ± 1 
Glycitein   34 ± 6 
a
   16 ± 1 
b
 
Equol 267 ± 15  259 ± 29  
Total isoflavones 499 ± 43 418 ± 37  
                           25-Week Feeding 
Daidzein 157 ± 26 
a
 272 ± 34 
b
 
Genistein                 19 ± 2                             23 ± 2 
Glycitein 67 ± 17                           116 ± 25 
Equol 413 ± 51 
a
 615 ± 54 
b
 
Total isoflavones 656 ± 88 
a
 1025 ± 107 
b
 
Values are the mean ± SEM.  n=5-6.  
Different letters within rows indicate significant differences between treatments (p<0.05).  
Total isoflavones = daidzein + glycitein + genistein + equol.  
Isoflavones were not detectable in urine from rats that consumed AIN-93G or 10% tomato 
powder. 
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Figure 2.1 Serum carotenoids in 7-day feeding study 
 
 
 
 
 
 
 
 
 
 
Values are mean ± SEM, n=6.  
* Indicates significant difference between treatments (p<0.05).  
β-carotene was below detection limits. 
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CHAPTER 3 
THE INTERACTIONS OF DIETARY TOMATO POWDER AND SOY GERM ON 
PROSTATE CARCINOGENESIS IN THE TRAMP MODEL 
1 
 
ABSTRACT 
 
The interactions between bioactive rich food components within a complex human diet for the 
inhibition of prostate carcinogenesis (PCa) are largely unknown and difficult to quantify in 
humans.  Tomato and soy products have each shown anti-PCa activity in laboratory studies.  The 
objective of this study was to determine the efficacy of dietary tomato and soy germ, alone and 
in combination, for the inhibition of prostate carcinogenesis in the transgenic adenocarcinoma of 
the mouse prostate (TRAMP) model.  At 4 weeks of age, male C57BL/6 x FVB TRAMP mice 
(n=119) were randomized to consume: AIN-93G control (n=29), 10% whole tomato powder 
(n=31) (TP), 2% soy germ powder (n=32) (SG) or 10% tomato powder with 2% soy germ 
powder (n=27) (TP+SG) for 14 weeks.  100% of mice fed the control diet had PCa, while PCa 
incidence was significantly lower in mice consuming TP (61%, p<0.001), SG (66%, p<0.001) 
and TP+SG (45%, p<0.001).  Although the protection offered by the combination of TP and SG 
was not synergistic, it was the most effective intervention.  TP, SG and TP+SG increased 
apoptotic index (AI) and modestly reduced the proliferative index (PI) in the prostate epithelium 
of TRAMP mice exhibiting primarily prostatic intraepethelial neoplasia. The dramatic reduction 
in the PI/AI ratio by the dietary interventions suggests that the control mice experience a stronger 
stimulus for malignant progression in the prostate microenvironment. Maximally effective and 
safe strategies for PCa prevention may result from optimizing combinations of nutrients and 
bioactives through an orchestration of dietary patterns.  
1 Zuniga KE, Clinton K, Erdman JW, Jr. The interactions of dietary tomato powder and soy 
germ on prostate carcinogenesis in the TRAMP model. Cancer Prev Research. In press.
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INTRODUCTION 
The combination of pharmacologic agents based upon selection of different mechanisms 
of action and non-overlapping toxicity has led to dramatic success in chemotherapy for certain 
cancers (1, 2). Yet, these principles have not been effectively applied to translational human 
cancer prevention studies.  Numerous epidemiological studies suggest that consumption of soy 
foods or tomato products is associated with a lower risk of prostate cancer (PCa) (3, 4) and this 
manuscript explores the potential benefit of combining them for PCa prevention. Soy products 
are a rich source of bioactive components, such as isoflavones, saponins, and lignans.  Tomatoes 
also provide various polyphenols, but are best known as a source of carotenoids such as lycopene 
and precursors phytoene and phytofluene (5).  Anti-PCa activity of soy or tomato components 
tested in cell culture or rodent models include protection against oxidative stress, inhibition of 
proliferation, enhanced sensitivity to apoptotic death signals, inhibition of inflammation and 
angiogenesis, and disruption of hormonal and growth factor signaling, among others (5-10).  
Experimental models of prostate tumorigenesis and carcinogenesis suggest that both soy and 
tomato products and several of their components have significant anti-cancer bioactivity (10-20).  
Our research team is particularly interested in examining the hypothesis that whole foods 
or novel food products containing a diverse array of bioactive phytochemicals, each individually 
at modest concentrations, may have greater activity for cancer prevention than any individual 
component developed as a pharmaceutical chemopreventive agent.  For example, we found that 
tomato powder is more effective than lycopene in reducing testosterone and NMU-induced 
prostate carcinogenesis in rodents (11, 21).  Recent in vitro evidence suggests that whole soy 
extract is more effective than individual isoflavones and sera from men consuming tomato paste 
was more effective than sera from men consuming lycopene alone in inducing cell cycle arrest 
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and apoptosis in PCa cells (22, 23).  People consume complex diets, yet there is limited research 
on the potential additive or interactive anti-cancer effects for consumption of multiple foods in 
combination.  The combination of tomato and broccoli has been shown to be more effective in 
reducing PCa progression in rats than when these vegetables are consumed individually (11), and 
the combination of dietary soy and tea, but not soy or tea alone, was effective in reducing 
inflammation and the development of prostate neoplasms in rats (12).  The reductionist approach 
of testing single bioactive components is useful in identifying potential anti-carcinogenic drugs 
or to provide insight into mechanisms of action for a food; however, it is increasingly important 
to investigate whole foods and combinations of foods, which may be more efficacious due to the 
presence of multiple bioactive compounds with complementary or synergistic activity.  
Epidemiological and laboratory studies support the hypotheses that diets rich in soy or 
tomato products may reduce the risk of PCa, and the limited, but positive research on the added 
benefits of whole foods and mixtures of foods suggest that a combination of tomato and soy may 
be more protective. High compliance for  a dietary intervention with the combination of tomato 
and soy products in a short phase II study in men with active PCa has previously been completed 
(24), supporting feasibility and justifying future investigations regarding the efficacy of the 
combination of these foods for biological activity in the prostate.  In vivo models provide an 
opportunity to examine the efficacy of interventions for future translation into clinical prevention 
studies.  The TRAMP (transgenic adenocarcinoma of the mouse prostate) model, which develops 
a prostate epithelium-specific cancer, is well-characterized and has been used extensively for 
investigation of dietary and pharmacologic chemoprevention strategies (25).  The objective of 
this study was to test the hypothesis that dietary interventions with tomato or soy germ, alone 
and in combination, would reduce the incidence of PCa in TRAMP mice. 
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MATERIALS AND METHODS 
Animals and Experimental Design. The University of Illinois Laboratory Animal Care 
Advisory Committee approved all animal procedures.  Male C57BL/6 x TRAMP mice 
heterozygous for the probasin-Tag transgene, female C57BL/6 and male and female FVB/NJ 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Female and male 
heterozygous TRAMP (C57BL/6) mice from our colony were bred with FVB/NJ mice to obtain 
[TRAMPxFVB/NJ] F1 offspring used for the study. Mouse tail DNA from male offspring was 
isolated with an Extract-N-Amp
TM
 Tissue PCR kit (Sigma Aldrich, St. Louis, MO), and mice 
were genotyped via PCR-based DNA screening.  Offspring were weaned at three weeks of age, 
individually housed in shoe-box cages under controlled conditions (12 h light-dark cycle, 22°C, 
60% humidity) and acclimated to a powdered, modified AIN-93G diet for one week.  At 4 weeks 
of age, mice were randomized to consume experimental diets: AIN-93G control (n=29), 10% 
whole tomato powder (n=31) (FutureCeuticals, Momence, IL), 2% soy germ powder (n=32) 
(Frutarom, North Bergen, NJ), and 10% tomato powder with 2% soy germ powder (n=27).  Diets 
were balanced for protein, fat, energy and fiber (Table 3.1), and stored at 4°C in the dark. Non-
transgenic litter mates (n=5 per group) were included in the study to confirm the effects of the 
transgene.  Mice were weighed weekly, and individual feed intake was measured three times a 
week when fresh diet was provided.  
At 18 weeks of age, mice were asphyxiated by CO2 and blood was collected by cardiac 
puncture. When possible, the prostate was microdissected into individual lobes (anterior, dorsal, 
lateral and ventral). Liver, testes and half of each prostate lobe were flash frozen in liquid 
nitrogen and stored at -80°C. All animals were thoroughly examined for gross metastases. 
59 
 
Lungs, liver sections, enlarged peri-aortic lymph nodes and half of each prostate lobe were fixed 
in 10% phosphate-buffered formalin overnight and transferred to 70% ethanol.  
Histopathology. Formalin fixed tissues were paraffin embedded and 4µm sections were 
stained with hematoxylin/eosin for pathologic grading. A blinded examiner (SKC), with 
extensive experience with transgenic mouse models of PCa, evaluated all prostate lobes for 
incidence and severity of pathology according to a grading scheme which has been previously 
described (26).  
Immunohistochemical analysis. Paraffin-embedded tissue sections (4 µm) were 
prepared, deparaffinized and rehydrated. Slides were placed in a decloaking chamber and treated 
in a citrate buffer (pH 6.0) for 30 seconds at 125ºC and 10 seconds at 90ºC for antigen retrieval. 
The subsequent steps were completed in a BioGenex i6000 Automated Staining System 
(BioGenex, San Ramon, CA). Endogenous peroxidase was quenched with a 3% H202 solution for 
15 minutes. Slides were blocked with Power Block™ (BioGenex) for 10 min, avidin blocked for 
15 min. and biotin blocked for 15 min.  Slides were incubated with rabbit anti-proliferating cell 
nuclear antigen (PCNA) antibody (Abcam, Cambridge, MA) or rabbit anti-cleaved caspase-3 
(Cell Signaling, Danvers, MA) for 30 minutes and visualized using a SuperSensitive™ Link-
Label IHC Detection System (Biogenex). Slides were stained with DAB and counterstained with 
hematoxylin. Tissue from mouse small intestine was used as a positive control for PCNA, and 
mouse thymus was used as a positive control for cleaved caspase-3. Negative control slides were 
obtained by omitting the primary antibody. Stained slides were scanned with a NanoZoomer 2.0-
HT digital slide scanner (Hamamtsu, Bridgewater, NJ) with Olympus Uplansapo 20X objective 
at 40x digital zoom, giving 0.23µm resolution.  Images were captured with NDP view software 
(Hamatsu). A representative image of the dorsal lobe and a representative image of the lateral 
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lobe of the prostate were captured for each mouse. Proliferation and apoptotic index were 
calculated as previously described in our laboratory (11, 27).  Apoptotic index (AI) from cleaved 
caspase-3 stained prostate sections was calculated as: AI = (cleaved caspase-3 positive cell count 
/ total epithelial cells counted) x 100. Proliferation index (PI) from PCNA stained prostate 
sections was calculated as: PI = (PCNA positive epithelial cell count / total epithelial cells 
counted) x 100. These indices were established by counting at least 1,000 cells from each image. 
The proliferation/apoptosis ratio was calculated as PI/AI.  
Carotenoid Analysis. Carotenoid extraction and analysis of diet, serum and tissues was 
performed as previously described (28).  Serum and testes were pooled within groups to facilitate 
HPLC detection of carotenoids; liver was extracted in duplicate.  
Isoflavone Analysis. Serum, prostate and diet samples were analyzed for isoflavones and 
their metabolites at The Ohio State University Comprehensive Cancer Center Nutrient and 
Phytochemical Analytic Shared Resource. Briefly, 100-200µL of serum was extracted with two 
volumes of acetonitrile. Extracts were resuspended in 2:1 acetonitrile/water, probe sonicated, 
centrifuged, and the supernatant was collected. This was repeated, and the supernatants were 
pooled, dried under nitrogen, and resuspended in 0.5 mL 2M acetate buffer (pH 5.5). Isoflavones 
were deconjugated with β-glucuronidase and sulfatase in 2 M acetate buffer (pH 5.5) for 1 h at 
37 °C. Digests were extracted twice with three volumes of ether and dried under nitrogen. 
Extracts were redissolved in 150µL methanol with bath sonication and filter through 0.2µm 
nylon before injection. Approximately 40 mg of prostate tissue was transferred to a 1.5mL 
microcentrifuge tube, suspended in 400µL of water and probe sonicated with a Fisher 
dismembrator at 35% amplitude setting for 5 seconds.  800µL of acetonitrile was added to 
induce protein precipitation and extract isoflavone metabolites. Samples were centrifuged for 5 
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min at 21,500 rcf to pellet solids, and supernatants were transferred to a 4mL glass vial.  Pellets 
were resuspended in 1.2mL of 2:1 acetonitrile/water, probe sonicated and centrifuged. 
Supernatants were pooled with first supernatants in a speedvac (45°C, 0.1 vacuum) until dry (1.5 
hrs). Residues were resuspended in 1mL of 2M acetate (pH 5.5) and isoflavones were 
deconjugated with β-glucuronidase and sulfatase in 0.2% NaCl for 3hrs at 37°C. Extracts were 
digested twice with three volumes ether (3mL).  Ether extracts were pooled, dried under 
nitrogen, dissolved in 150µL methanol with bath sonication, and filtered through 0.2 µm nylon 
before injection. Samples were analyzed by UPLC/MS with a Phenomenex Synergi Fusion RP 
Column (2x50mm, 2.5µm) and quadrupole mass spectrometer (Quattro Ultima, Micromass, 
Manchester, UK) via an electrospray probe operated at negative polarity.  Authentic standards of 
daidzein, dihydrodaidzein, o-desmethylangolensin, equol, glycitein, genistein, and 
dihydrogenistein were used as external calibrants. 
Serum VEGF.  Serum VEGF was analyzed by ELISA according to the manufacturer’s 
instructions (R&D Systems, Minneapolis, MN). 
Statistical analysis.   SAS (version 9.3; SAS Institute, Cary, NC) was used for all 
statistical analysis, and a p<0.05 was considered significant. Serum lycopene and isoflavones 
were analyzed by a Student’s t- test. Weight gain, feed intake, gain:feed ratio, serum VEGF, 
proliferation index and apoptotic index were compared by two-tailed analysis of variance using 
the mixed model procedure in SAS with a Dunnett’s post-hoc test. Fisher’s exact test was used to 
compare incidence of pathology between an experimental group and the controls.  
 
 
RESULTS 
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All experimental diets were readily consumed by TRAMP mice. There were no 
significant differences in weight gain or gain:feed ratio between any dietary intervention group 
and the control group (Table 3.2). Feed intake in the TP and SG groups was not significantly 
different from the controls. The average daily feed intake in the TP+SG group was significantly 
lower than the control group (p=0.003); however, this minimal difference in feed intake of 25%  
is likely not biologically significant.  
Tomato powder feeding increases serum and tissue lycopene accumulation. 
Lycopene, the primary carotenoid in tomatoes, was detected in serum and tissues of mice 
consuming TP or TP+SG (Table 3.3). Mean serum lycopene levels were significantly higher in 
TP fed mice than mice fed TP+SG (p-0.03). Testicular lycopene was nearly three times higher in 
mice that consumed TP compared to TP+SG (p=0.006).  Although not statistically significant, 
lycopene accumulation in the prostate tumors (p=0.2) and liver (p=0.3) was also lower in TP+SG 
fed mice.  
Isoflavones and isoflavone metabolites are detected in serum and prostate of 
TRAMP mice consuming soy germ. Parent isoflavones and isoflavone metabolites were 
detected in the serum and prostate of SG and TP+SG fed mice (Table 3.4). Individual and total 
isoflavone concentrations in the serum and prostate were not significantly different between SG 
or TP+SG fed mice. Serum genistein was below detection limits in 3 out of 7 SG fed mice and 6 
out of 8 TP+SG mice (limit of detection= 5x10-9 mol/L). Equol, a metabolite of daidzein, was 
the primary isoflavone detected in the serum and prostate, and equol concentrations were higher 
than all other metabolites and parent isoflavones combined.  
Range of pathology identified in TRAMP mice. Non-transgenic mice in all of the 
dietary groups had histologically normal prostates.  At the time of necropsy (age 18 weeks), all 
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TRAMP mice had evidence of prostatic intraepithelial neoplasia (PIN) or PCa.  Representative 
images of the range of pathological progression in mice observed are shown in Figure 3.1. 
Cancerous lesions, categorized as well-differentiated (WD), moderately-differentiated (MD) or 
poorly-differentiated (PD) carcinoma, were identified in 68% of the TRAMP mice (Table 3.5). 
As previously described in the TRAMP model, cancer lesions were more frequent in the dorsal, 
lateral and ventral lobes (29), and the most common pathology was PD carcinoma.   
Consumption of tomato powder, soy germ, and the combination significantly 
reduced prostate cancer incidence. Cancer incidence was defined as the presence of a 
cancerous lesion (WD, MD, PD) in at least one prostatic lobe. 100% of mice fed control diets 
showed evidence of PCa in at least one lobe, and compared to the controls, overall incidence was 
significantly lower in TRAMP mice consuming TP (61%, p<0.001), SG (66%, p<0.001) and 
TP+SG (45%, p<0.001) (Table 3.6). In parallel to the low cancer incidence, TRAMP mice in the 
dietary intervention groups had significantly higher incidence of non-cancerous PIN lesions 
compared to the controls.  We also employed a histopathological scoring system to assign a 
numerical score to each lobe based on the severity and overall extent of pathology within the 
prostate (26).  Reassuringly, the quantitative numerical scoring system also identified a 
significant impact of diet on prostate carcinogenesis.  The most severe lesion score in the 
prostate was significantly lower in the TP (14.7 ± 1.1, p<0.01), SG (15.6 ± 1.1, p=0.03) and 
TP+SG (13.5 ± 1.2, p<0.001) groups compared to the control (19.3 ± 0.4).  
Dietary interventions impacted the severity of carcinogenesis in prostate lobes. 
Compared to the controls, PCa incidence in the SG group was significantly lower in the lateral 
and anterior lobes, and TP and TP+SG groups had significantly lower PCa incidence in the 
dorsal, lateral and ventral lobes (Table 3.7). The incidence of MG PIN in the anterior lobe was 
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significantly higher in TP, SG and TP+SG groups compared to the controls due to the higher 
incidence of more severe pathology in the controls. Although not significantly different from TP 
or SG, PCa incidence in the dorsal, lateral and ventral lobes was lowest in the TP+SG group.  
Dietary impacts on regional lymph node metastases. Due to our desire to examine 
early phases of carcinogenesis and the young age (18 weeks) at which mice were necropsied, the 
overall metastasis rate was low and the study lacked statistical power to fully assess 
local/regional or distant metastatic rates.  However, the descriptive data reinforces the 
conclusions regarding dietary impact on prostate disease.  The incidence of gross lymph node 
metastasis was lower in TP, SG, and TP+SG fed mice compared to the controls (Table 3.8).  In 
mice with advanced, diffuse, PD adenocarcinoma (n=25), we observed that 6 mice had distant 
micrometastases, defined as the presence of microscopic T-antigen positive prostate cancer cells 
in the liver and/or lungs (data not shown), and half of those animals (n=3) were control fed mice. 
Dietary interventions with TP, SG, and TP+SG increased apoptosis. We chose a similar 
histological subset of prostate samples to examine proliferation and apoptotic index.  Sections 
from the dorsal and lateral prostate lobes in which the predominant pathology was PIN were 
stained and quantitated. The apoptotic index in the prostate of control-fed mice was nearly half 
that of mice consuming TP, SG and TP+SG (Table 3.9).  Proliferation in TP, SG and TP+SG 
groups was quantitatively lower but not significantly different from the controls (main effect of 
diet, p=0.4).  The ratio of the proliferative index to the apoptotic index in control-fed mice was 
over two times higher than mice consuming TP, SG and TP+SG (Table 3.9).    
Serum VEGF is increased in mice with poorly differentiated and metastatic 
adenocarcinoma. Serum VEGF was not significantly different between dietary groups (Figure 
3.2).  Irrespective of diet, we observed no major overall elevation in serum VEGF in TRAMP 
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mice without metastases compared to normal, wild-type mice (Figure 3.3).  However, serum 
VEGF levels were significantly elevated in TRAMP mice that had PD adenocarcinoma with 
metastasis (Figure 3.3), but since too few mice had metastatic disease, the study was 
underpowered to assess an impact of diet on cancer-associated elevations in serum VEGF. 
DISCUSSION 
There are a number of in vivo and in vitro studies that have investigated the anti-
carcinogenic properties of pure phytochemicals derived from foods using the principles of 
pharmacognosy and pharmacology in hopes of developing novel drugs for chemoprevention.  
However, there are far fewer studies focusing upon interventions with whole foods or novel 
processed food products.   In this study we examine the combination of soy and tomato products 
for their anticancer activity in the TRAMP model in order to guide future development of food 
products and identify protective dietary patterns for human PCa prevention strategies. 
Preclinical rodent studies of prostate carcinogenesis with tomato products alone have 
been promising. The current study shows that consumption of 10% tomato powder reduced the 
overall incidence of early PCa in the TRAMP model by nearly 40% (P< 0.001).  Tomato powder 
at 10% of the diet has previously been shown to increase survival and reduce the incidence of 
advanced, poorly-differentiated PCa in the TRAMP model (13), and interventions in other rodent 
models also support the protective effects of tomato products against prostate carcinogenesis (11, 
14, 21).  Lycopene concentrations in the serum (0.36 – 0.84 µM) and prostate (0.11 – 0.48 
nmol/g tissue) of TRAMP mice in this study are comparable to levels observed in men 
consuming 25-30 mg lycopene/day from tomato products (24, 30, 31), which can be achieved by 
intake of approximately one cup of tomato sauce, ½ cup tomato paste or 6 cups of raw tomatoes. 
Therefore, the tissue and serum concentrations of lycopene achieved in this study can be 
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obtained in humans by intake of whole foods with an array of bioactives without the use of pure 
lycopene supplements. 
The majority of interventions with soy protein isolate or soy phytochemical extracts in 
rodent models of PCa have shown anti-cancer activity, suggesting that soy consumption may 
inhibit carcinogenesis, reduce tumorigenesis, and reduce expression of biomarkers related to 
proliferation or angiogenesis (15, 32).  Soy germ was selected for study as it is a phytochemical-
rich fraction of the soybean that can be used more easily to produce novel functional foods for 
future cancer prevention studies (33, 34).  To our knowledge, this is the first study to evaluate the 
potential anti-carcinogenic properties of soy germ. Soy germ, the hypocotelydon of the soybean, 
is separated during milling of whole soybeans and is a concentrated source of bioactives 
including isoflavones, saponins and phytosterols. In contrast to soy protein isolates, 
concentrations of daidzein and glycitein in soy germ are considerably higher than genistein (as 
quantified by LC/MS).  The anti-carcinogenic properties of genistein have been extensively 
studied and may be one contributor to the anti-cancer activity associated with soy consumption 
(35). However, in our study, diets containing soy germ provided a modest 45mg genistein/kg 
diet, which is substantially lower than the range of doses (250-1000 mg genistein/kg diet) 
previously suggested to be protective with in vivo studies (18-20, 36-38).  In fact, genistein was 
below detection limits in the serum from several of the mice that consumed diets containing soy 
germ and was only 4-5% of total isoflavones in the prostate.  Glycitein was nearly 40% of total 
isoflavones provided in the diet, yet was only 4-5% of total isoflavones in the serum and 
prostate. Bioavailability of glycitein has not been studied as extensively as the other isoflavones. 
Glycitein in the diet was ten times higher than genistein; conversely, serum and prostate 
concentrations of glycitein and genistein were similar. Interestingly, in healthy adults, daidzein 
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and glycitein were more bioavailable than genistein after consumption of soy germ with a similar 
isoflavone profile as our product (39). After ingestion of a soy germ supplement (55 mg total 
isoflavone aglycone equivalents) by healthy, adult males, pharmacokinetic parameters of 
daidzein and glycitein did not differ, suggesting similar bioavailability of these isoflavones (40). 
In humans, similar glycitein pharmacokinetic parameters were seen in equol versus nonequol 
producers (40). In vitro fecal fermentation of glycitein did not change when fermented with 
genistein or daidzein (41), suggesting that at the doses studies, isoflavones did not compete for 
metabolism by intestinal microbiota, and the efficient equol production from daidzein in rats 
should not interfere with glycitein bioavailability. 
Equol, produced from the metabolism of daidzein by intestinal microbiota, was the 
predominant isoflavone in the serum and prostate.  Equol has a longer half-life and is a more 
potent antioxidant than parent isoflavones (42). Equol has also been shown to have a greater 
affinity for estrogen receptors than daidzein and can concentrate in the prostate and the prostatic 
fluid at higher concentrations than genistein (42, 43). However, it is estimated that only 30-40% 
of the Western population can metabolize daidzein to equol, and it is of increasing interest to 
determine if health benefits from soy consumption are related to equol synthesis or other 
metabolites either produced by the host or the intestinal microbiota. Thus, our findings suggest 
that other soy phytochemicals in addition to genistein may contribute to the anti-cancer activity 
of soy germ. Serum and prostatic isoflavone concentrations in this study are comparable to those 
identified in men consuming soy foods or isoflavone supplements (44-46).  Asian populations, 
which historically have demonstrated a substantially lower incidence of PCa compared to 
Western countries (47), consume an average of 25-50 mg isoflavones/day (48), which can be 
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achieved in the diet by consumption of 1-2 servings of soy foods (one serving = 4 oz tofu, 1 oz 
soy nuts or 8 oz soymilk).   
Soy isoflavones and tomato carotenoids have distinctly different mechanisms of 
absorption, yet, long-term combined consumption of TP+SG resulted in slightly reduced serum 
and testicular lycopene than when TP was consumed alone. Results from this study support our 
previous findings where SG consumption significantly reduced carotenoid accumulation in the 
liver, testes, seminal vesicles and prostate of male rats (28). In our previous study, reduced 
carotenoid bioaccumulation was not explained by gene expression of scavenger receptor class B 
type I (a protein involved in carotenoid absorption) or carotenoid metabolizing enzymes in the 
prostate, liver or duodenal mucosa (28). Reduced lycopene bioaccumulation in rats consuming 
SG suggests a food-food interaction that impacts carotenoid absorption and/or metabolism.  
Future studies investigating combinations of foods should measure bioactives of interest to 
identify potential interactions between foods that may impact bioavailability. 
It is a challenge to identify specific mechanisms of action when investigating whole food 
products containing an array of bioactives with diverse activities; indeed, many pathways may be 
modulated.  We assessed the dynamic changes in the epithelial cell proliferation/apoptotic 
relationship.  In order to accurately examine this relationship we chose a similar area of the 
prostate (dorsal and lateral lobes) exhibiting the same histopathologic grade of cancer 
progression (PIN) from mice on each diet.  We clearly observed that TP, SG and TP+SG 
increased apoptotic index (AI) and modestly reduced the proliferative index (PI), resulting in a 
dramatic reduction in the PI/AI ratio, a finding that would favor the lack of accumulation of 
malignant epithelial cells in the dietary interventions groups compared to the controls. These 
findings from an in vivo and very aggressive model support the in vitro findings suggesting that 
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many polyphenols in soy and tomato can inhibit growth factor signaling transduction pathways 
and enhance sensitivity to activation of apoptotic cascades (17, 49-51). Tomato sauce 
consumption has previously been reported to increase apoptosis in both PCa and benign prostatic 
hyperplasia (52).  In vitro, isoflavone and isoflavone metabolites induced apoptosis in benign 
prostatic epithelial cells at concentrations within ranges identified in the prostatic fluid of men 
consuming soy (53). PCNA has a long half-life and is also involved in DNA damage repair; 
therefore, PCNA positive cells may not always be actively proliferating cells. More sensitive 
markers of proliferation may be able to detect differences in proliferation between groups.   
We have previously observed a decline in serum VEGF in men with metastatic PCa fed 
tomato and soy components (24). We did examine serum VEGF in this study, but the early age 
of termination at 18 weeks, when most mice have microscopic cancer or PIN, was too early for 
the clear assessment of diet on serum VEGF or other markers of angiogenesis.  Indeed, when 
evaluating our data, only mice with advanced, poorly differentiated cancers with regional or 
distant metastases showed elevations in serum VEGF.  Thus, our study, terminated at an early 
point in the carcinogenesis process, prevented an assessment of the impact of diet on serum 
VEGF as seen in our human study.  
Interestingly, we observed a 30% reduction of PCa by TP and SG, a level of protection 
similar to that calculated from meta-analyses of epidemiological studies measuring soy or tomato 
product consumption (3, 4).  This is the first study to investigate the efficacy of a combination of 
tomato and soy for inhibition of prostate carcinogenesis in an animal model. 
Over half of the TRAMP mice that consumed the combination of TP+SG were without a 
single cancerous lesion in the prostate compared to 100% cancer incidence in the control group. 
Interestingly, in PCa patients, lycopene supplementation was more effective at reducing serum 
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prostate specific antigen (PSA) progression than the combined supplementation of lycopene and 
soy isoflavones (54), suggesting a potential negative interaction between soy isoflavones and 
lycopene.  The small clinical trial had no control group and did not measure the efficacy of soy 
isoflavones alone; therefore, it is difficult to know if the soy isoflavones had any impact on 
cancer outcomes and if there was truly a negative interaction between these bioactive 
components. In our trial, the combination of TP and SG was quantitatively the most effective 
intervention and suggests a positive interaction between tomato and soy foods for prevention of 
PCa. 
This study reinforces the public health recommendations of many organizations such as 
the American Institute for Cancer Research and the United States government through the 2010 
Dietary Guidelines for Americans which recommend that a variety of fruits and vegetables 
should serve as the foundation of a healthy diet (55, 56).  In addition to supporting national 
public health goals, this work suggests that continued efforts to develop novel functional foods 
containing an array of bioactives are a reasonable strategy for PCa prevention.  The 
demonstrated benefit from the combination of dietary components that have been selected based 
upon evidence derived from laboratory and epidemiologic studies provides a stimulus for food 
scientists to develop novel tomato-soy food products with defined and consistent composition 
(24, 33) for future clinical trials.  Maximally effective and safe strategies for PCa prevention may 
result from optimizing combinations of nutrients and bioactives through an orchestration of 
dietary patterns.   
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FIGURES AND TABLES 
 
Table 3.1. Composition of experimental diets 
g/100g  total diet 
 Control 
10% Tomato 
Powder 
a
 
2% Soy 
Germ 
b
 
10% Tomato Powder + 
2% Soy Germ 
ab
 
Cornstarch 39.75 36.5 39.75 36.5 
Casein 20.0 18.7 19.12 17.82 
Maltodextrin 13.2 9.95 13.2 9.95 
Sucrose 10.0 10.0 10.0 10.0 
Fiber 
c
 5.0 3.3 4.36 2.66 
Mineral Mix
 d
 3.5 3.5 3.5 3.5 
Vitamin Mix 
e
 1.0 1.0 1.0 1.0 
L-Cystine 0.3 0.3 0.3 0.3 
Choline Bitrate 0.25 0.25 0.25 0.25 
Cottonseed Oil 7.0 6.5 6.52 6.02 
Tomato Powder
 f
 0.0 10.0 0.0 10.0 
Soy Germ
 g
 0.0 0.0 2.0 2.0 
a 
Contains 268 µg total lycopene per gram of diet 
b 
Contains 200 µg total daidzein, 156 µg total glycitein, and 45 µg total genistein per gram of 
diet. For all three isoflavones, glucosides accounted for 58%, acetyl glucosides 32-39%, and 
aglycones 4-10% of total isoflavones. 
c
 Non-nutritive cellulose, 
d
 AIN93-MX formulation, 
e
 AIN93-VX formulation 
f 
 FutureCeuticals Tomato Powder 20 N8 
g
  Frutarom SoyLife® Complex Micro  
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Table 3.2. Body weight and feed intake 
 
 AIN93-G 
Control 
10% Tomato 
Powder 
2% Soy 
Germ 
10% Tomato 
Powder + 2% Soy 
Germ 
Weight Gain (g) 16.5 ± 0.7 14.6 ± 0.7     17.9 ± 0.7 17.1 ± 0.7 
Feed Intake (g/day)  5.71 ± 0.03   5.73 ± 0.03 5.73 ± 0.03      5.57 ± 0.03* 
Gain:Feed Ratio 
(g:g) 
 0.029 ± 0.001   0.026 ± 0.001   0.32 ± 0.001    0.031 ± 0.001 
Values are means ± SEM.  
* within rows indicate significantly different than the controls (p<0.05) 
 
 
Table 3.3. Serum and tissue lycopene 
Values are mean ± SEM. 
 * within rows indicate significant difference between treatments (p<0.05).   
Liver and gonadal adipose n=7, serum and testes n=5, seminal vesicles n=4-6, tumor n=5-8. 
Lycopene was not detected in animals consuming AIN-93G or 2% soy germ diets.  
 
  
 10% Tomato 
Powder 
10% Tomato Powder + 2% Soy 
Germ 
Serum (µM) 0.67 ± 0.07   0.44 ± 0.04* 
Liver (nmol/g) 4.56 ± 0.91  3.14 ±  0.56 
Prostate Tumor  (nmol/g) 0.25 ± 0.05                        0.18 ± 0.04 
Gonadal Adipose (nmol/g) 0.90 ± 0.19 0.65 ± 0.13 
Seminal Vesicles (nmol/g) 0.05 ± 0.01 0.04 ± 0.01 
Testes (nmol/g) 1.42 ± 0.23   0.47 ± 0.10* 
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Table 3.4. Serum and prostatic isoflavones 
Values are means ± SEM. Serum n=7-8, prostate n=4.  
a
 – genistein was below detection limits in 3 mice in the 2% soy germ group and 6 mice in the 
10% tomato group + 2% soy germ group. 
Isoflavones were not detected in the analysis of AIN-93G or 10% tomato powder diets; therefore 
serum and prostate from mice consuming these diets were not analyzed for isoflavones.  
 
 
 
 
 
 
 
 
 
 2% Soy Germ 10% Tomato Powder + 2% Soy 
Germ 
Serum (µM) 
Total Isoflavones 3.93 ± 0.60 4.02 ± 0.26 
Total Parent 0.61 ± 0.22 0.74 ± 0.14 
     Daidzein 0.29 ± 0.85 0.48 ± 0.09 
     Glycitein 0.14 ± 0.39 0.24 ± 0.05 
     Genistein
a 
 0.18 ± 0.10 0.01 ± 0.01 
Total Metabolites  3.32 ± 0.49 3.28 ± 0.17 
     Dihydrodaidzein  0.02 ± 0.01 0.08 ± 0.03 
     Dihydrogenistein 0.01 ± 0.01 0.03 ± 0.01 
     O-desmethylangolensin  0.03 ± 0.01 0.07 ± 0.03 
     Equol  3.26 ± 0.49 3.10 ± 0.18 
Prostate (nmol/g) 
Total Isoflavones 0.201 ± 0.083 0.224 ± 0.068 
Total Parent 0.048 ± 0.022 0.041 ± 0.005 
     Daidzein 0.035 ± 0.017 0.029 ± 0.003 
     Glycitein 0.010 ± 0.004 0.008 ± 0.002 
     Genistein 0.003 ± 0.001 0.003 ± 0.001 
Total Metabolites  0.152 ± 0.062 0.183 ± 0.063 
     Dihydrodaidzein  0.032 ± 0.014 0.034 ± 0.011 
     Dihydrogenistein 0.003 ± 0.001 0.003 ± 0.001 
     O-desmethylangolensin  0.001 ± 0.001 0.002 ± 0.001 
     Equol  0.117 ± 0.047 0.142 ± 0.050 
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Table 3.5. Distribution of pathology (most severe lesion) by prostatic lobe in 18-week old 
 TRAMP mice.  
 
 
PIN  Adenocarcinoma 
 
LG MG HG  WD MD PD 
Anterior 3% 39% 53%  0% 3% 2% 
Ventral 5% 24% 17%  3% 3% 48% 
Dorsal 2% 21% 27%  4% 2% 44% 
Lateral 1% 21% 18%  8% 3% 49% 
 
PIN = prostatic intraepithelial neoplasia, LG = Low-Grade, MG = Moderate-Grade, HG = High-
Grade, WD = Well-Differentiated, MD = Moderately-Differentiated, PD = Poorly-Differentiated. 
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 Table 3.6. Analysis of histopathological data based upon the most severe lesion found in the 
entire prostate for TRAMP mice fed tomato powder or soy germ, alone or in combination.   
 
LG = Low-Grade, MG = Moderate-Grade, HG = High-Grade, PIN= prostatic intraepithelial neoplasia, 
WD = Well-Differentiated, MD = Moderately-Differentiated, PD = Poorly-Differentiated. Results are the 
incidence of each histopathologic grade and overall prostate cancer incidence (sum of WD-PD) within 
dietary groups. * p<0.05, ** p< 0.01, *** p<0.001 compared to control group by Fisher’s exact test. 
 
 
 
  
 
 PIN  Adenocarcinoma  
Prostate Cancer 
(WD, MD, PD) Treatment 
 
n LG MG HG 
 
WD MD PD 
 
Control 29 0% 0% 0%  10% 7% 83%  100% 
10% Tomato 31 0% 7%  32%
***
  6% 0% 55%
*
       61%
***
 
2% Soy Germ 32 0% 6% 28%
**
  6% 7% 53%
*
       66%
***
 
10% Tomato + 2% Soy Germ 27 0% 7%  48%
***
  0% 4% 41%
**
       45%
***
 
77 
 
Table 3.7. Histopathological analysis (most severe lesion) of individual prostate lobes in 
TRAMP mice fed tomato powder or soy germ, alone or in combination 
 
 
 
PIN 
 
Adenocarcinoma 
Prostate  
Cancer  
(WD, MD, 
PD)  n LG MG HG 
  
WD MD  PD 
Dorsal Prostate 
 
   
 
    
     Control 29 0% 4% 17% 
 
10% 7% 62% 79% 
     10% Tomato 31 0%  26%* 35% 
 
7% 0%  32%*   39%** 
     2% Soy Germ 32 6%      16% 28% 
 
0% 0% 50% 50% 
     10% Tomato + 2% Soy Germ 27 3%    41%*** 26% 
 
0% 0%  30%*    30%*** 
Lateral Prostate     
 
    
     Control 29 0% 0% 14% 
 
7% 10%  69% 86% 
     10% Tomato 31 0% 26%** 22% 
 
10% 0% 42%*   52%** 
     2% Soy Germ 31 3% 32%*** 13% 
 
0% 0%  52%   52%** 
     10% Tomato + 2% Soy Germ 27 0% 41%*** 18% 
 
8% 0% 33%*    41%*** 
Ventral Prostate          
     Control 29 0% 14% 7% 
 
7% 7% 65% 79% 
     10% Tomato 31 7% 32% 22% 
 
3% 0%  36%*   39%** 
     2% Soy Germ 32 6% 28% 7% 
 
3% 3% 53% 59% 
     10% Tomato + 2% Soy Germ 27 8% 22% 33%* 
 
0% 0% 37%   37%** 
Anterior Prostate     
 
    
     Control 27 0% 11% 74% 
 
0% 8% 7% 15% 
     10% Tomato 28 4%     57%***  39%* 
 
0% 0% 0% 0% 
     2% Soy Germ 30 3%  43%** 54% 
 
0% 0% 0%   0%* 
     10% Tomato + 2% Soy Germ 22 5%  45%** 45% 
 
0% 5% 0% 5% 
 
LG = Low-Grade, MG = Moderate-Grade, HG = High-Grade, PIN= prostatic intraepithelial neoplasia, WD = Well-
Differentiated, MD = Moderately-Differentiated, PD = Poorly-Differentiated. Results are the incidence of each 
histopathologic grade and overall prostate cancer incidence (sum of WD-PD) within dietary groups. * p<0.05,  
** p<0.01, *** p<0.001 compared to control group by Fisher’s exact test. 
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Table 3.8. Dietary impacts on peri-aortic lymph node metastasis in TRAMP mice 
 Metastasis Incidence 
Control 17.2% 
10% Tomato Powder 9.4% 
2% Soy Germ 12.9% 
10% Tomato Powder + 2% Soy Germ 11.1% 
 
Table 3.9. Proliferative and apoptotic indices in TRAMP mice 
 
Control 10% Tomato 2% Soy Germ 
10% Tomato + 
2% Soy Germ 
Proliferative Index (%) 81 ± 3 77 ± 4 74 ± 3 76 ± 4 
Apoptotic Index (%) 0.7 ± 0.2 1.2 ± 0.2* 1.4 ± 0.2* 1.3 ± 0.2* 
PI/AI Ratio 154 ± 17 72 ± 18** 63 ± 17** 70 ± 18** 
Data are mean ± SEM. n=10-11. * p<0.05, ** p<0.01 compared to the control group.  
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Figure 3.1. Prostate pathology in 18-week old TRAMP mice.  
(A) Low-grade PIN, (B) Moderate-grade PIN, (C) High-grade PIN, (D) Well-differentiated 
adenocarcinoma, (E) Moderately-differentiated adenocarcinoma, (F) Poorly-differentiated 
carcinoma.  
Figure 3.2. Serum VEGF in TRAMP mice by diet 
Data are mean ± SEM. n=16-19. 
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Figure 3.3. Serum VEGF in TRAMP mice by pathology 
 
 
Data are mean ± SEM. * p<0.01 compared to the control group 
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CHAPTER 4 
BROCCOLI CONSUMPTION MODULATES EXPRESSION OF MARKERS OF THE 
EPITHELIAL TO MESENCHYMAL TRANSITION IN TRAMP MICE 
1
 
 
ABSTRACT 
Prostate cancer (PCa) is the second leading cause of cancer deaths in men. Consumption of 
cruciferous vegetables, such as broccoli, has been suggested to reduce the risk of aggressive PCa.  
We have previously found that broccoli powder consumption did not reduce the incidence of 
PCa in transgenic adenocarcinoma of mouse prostate (TRAMP) mice. However, based on 
epidemiological evidence, broccoli consumption may result in a less aggressive PCa phenotype 
and reduced risk of metastatic PCa.  Clinical evidence suggests that expression of markers of the 
epithelial to mesenchymal transition (EMT) is associated with a more invasive and aggressive 
PCa.  Our objective was to investigate the effects of consumption of standard broccoli and 
methyl-jasmonate (MeJa) treated broccoli, a broccoli higher in bioactive indole-glucosinolates, 
on expression of markers of EMT in PCa of TRAMP mice. 
Focused qRT-PCR arrays were used to measure expression of 84 EMT related genes in 
the prostate. The expression profile in well-differentiated adenocarcinoma of TRAMP mice 
differed from benign prostate and was indicative of an EMT-like state. Compared to control-fed 
TRAMP mice, the consumption of standard or MeJa broccoli altered the expression profile of 
EMT-related genes. Validation of genes of interest identified a 2-fold lower expression of N-
cadherin in mice fed either standard (p=0.04) or MeJa (p=0.02) broccoli. Immunohistochemical  
_____________________________________________________________________________ 
1 This chapter was the result of collaboration between the following authors: Krystle E. Zuniga, 
Ann G. Liu, Elizabeth Jeffery and John W. Erdman, Jr.  
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analysis of E-cadherin and N-cadherin across a range of pathology in the TRAMP model 
suggests that the loss of E-cadherin and the gain of N-cadherin is correlated with cancer 
progression and metastasis. Expression of transcription factors Snail, Slug and Twist, modulators 
of cadherin expression, were not altered by diet. This is the first study, to our knowledge, to 
determine the effects of whole broccoli consumption on EMT. In this study, all prostates used for 
analyses had well-differentiated adenocarcinoma; therefore, our findings suggest that even 
within the same cancer stage, broccoli containing diets can significantly alter the molecular 
profile of a cancer to reduce the risk of a more aggressive disease.  
INTRODUCTION 
Prostate cancer (PCa) is the second leading cause of cancer deaths in U.S. men (1). The 
five year survival rate for PCa is nearly 100%, but when the cancer metastasizes, survival rate 
drops dramatically to less than 30% (1, 2).  Men do not die from the primary PCa, but from 
complications of metastasis, when cancer cells enter circulation and proliferate at a new site, 
primarily lymph nodes and bone (3). A growing body of evidence suggests that the epithelial to 
mesenchymal transition (EMT) may be involved in the gain of invasive and metastatic behavior 
of PCa cells.  In non-cancerous tissue, EMT is a normal process involved in wound healing and 
gastrulation (4). EMT is typically characterized by a decrease in expression of epithelial genes, 
an increase in expression of mesenchymal genes and altered cell morphology – allowing for cells 
to gain mobility and invasive characteristics (5). In PCa, expression of markers of EMT, 
including low expression of the epithelial cell adhesion protein E-cadherin (Cdh1) and the gain 
of the mesenchymal protein N-cadherin (Cdh2), have been associated with reduced survival and 
increased risk of metastasis (6).  The association of markers of EMT with metastatic behavior 
90 
 
suggests that reversing or inhibiting EMT in PCa may reduce the risk of progression to an 
aggressive and metastatic disease.    
Epidemiological evidence suggests that broccoli consumption may reduce the risk of 
aggressive PCa. In the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, the risk of 
aggressive (RR = 0.76) and extraprostatic PCa (RR=0.55) was significantly lower in men who 
consumed more than one serving a week of broccoli compared to those that consumed  less than 
one serving a month (7).  A significant trend of reduced risk of advanced PCa by cruciferous 
vegetable consumption was also identified in a multiethnic case-control study (8). In the Health 
Professionals Follow-up study, men in the highest quartile of cruciferous vegetable intake 
(median intake = 0.92 servings/day) post-PCa diagnosis had a nearly 60% reduced risk of cancer 
progression (9).  The potential mechanisms by which broccoli consumption is protective against 
aggressive PCa have not been investigated, but studies with broccoli bioactives, such as indole-
3-carbinol and sulfurophane, suggests that these compounds may have anti-EMT activity.  In 
vitro, I3C inhibited the migration of PCa cells by increasing phosphorylation of β-catenin for 
subsequent degradation (10). I3C, via i.p. or i.v. injections, inhibited incidence of lung 
metastases and significantly increased survival in the MAT-LyLu rodent model of PCa (11).  
Oral gavage with sulfurophane in TRAMP mice significantly reduced the incidence of 
pulmonary metastasis (12), and a follow-up in vitro study found that this may have been due to 
sulfurophane’s ability to inhibit PCa cell migration (13).  Although the individual bioactives in 
broccoli have been suggested to inhibit EMT and reduce the incidence of metastasis, no previous 
studies have examined the anti-metastatic properties of whole broccoli consumption in PCa. 
We have previously found that consumption of standard broccoli or methyl jasmonate 
(MeJa)-treated broccoli, which is higher in bioactive indole glucosinolates, did not reduce the 
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incidence of PCa in transgenic adenocarcinoma of mouse prostate (TRAMP) mice (14), but this 
study did not follow mice through to metastatic cancer. Broccoli consumption has been 
associated with a reduced risk of aggressive PCa (9), and clinical evidence suggests that, 
independent of cancer stage, expression of markers of EMT may be predictive of poor survival 
and increased risk of metastasis (6, 15).  Therefore, the objective of this study was to investigate 
the effects of broccoli consumption on expression of markers of EMT in TRAMP mice. 
MATERIALS AND METHODS 
Animals and Experimental Design.  Male C57BL/6 x TRAMP mice (n=99) (The 
Jackson Laboratory, Bar Harbor, ME) were obtained at 5-7 weeks of age, individually housed, 
and randomized  to consume (n=33/group): AIN-93G control, 10% standard broccoli powder, or 
10% methyl jasmonate - treated (MeJa) broccoli powder.  Diet analysis confirmed that total 
glucosinolate levels were more than five times higher in the MeJa treated broccoli compared to 
standard broccoli (p<0.05) (14).  At 20 weeks of age, mice were asphyxiated by CO2, and one 
section of each prostate lobe was flash frozen in liquid nitrogen and another section was 
preserved in 10% formalin.  Frozen prostate lobes were stored at -80°C until processed for 
mRNA analysis. Formalin-fixed prostate lobes have been previously graded for stage of 
pathology by trained pathologists according to a well-defined grading scheme (16).  The 
University of Illinois Laboratory Animal Care Advisory Committee approved all animal 
protocols and procedures. 
Immunohistochemical analysis. Prostates from 18 week-old, AIN-93G fed TRAMP 
mice and non-transgenic littermates from a previously-conducted trial (See chapter 3) were 
selected for immunohistochemical analysis to represent a range of pathology: normal (non-
transgenic), well- to moderately-differentiated adenocarcinoma, poorly-differentiated carcinoma, 
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and invasive (metastasized), poorly-differentiated carcinoma. Paraffin-embedded tissue sections 
(4 µm) were prepared, deparaffinized and rehydrated.  Slides were heat treated with BioGenex 
Citra Plus (BioGenex, San Ramon, CA) for 30 minutes (E-cadherin) or 20 minutes (N-cadherin) 
for antigen retrieval. The subsequent steps were completed in a humid chamber using the Dako 
EnVision
TM
+ System - HRP kit (Carpinteria, CA) for rabbit antibodies.  Endogenous peroxidases 
were quenched with a peroxidase block for 15 minutes, then blocked with common antibody 
diluent (BioGenex) for 30 minutes. Slides were incubated with rabbit polyclonal E-cadherin 
antibody (1:250) (Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit polyclonal N-cadherin 
antibody (5µg/mL) (Abcam, Cambridge, MA) for 60 minutes and visualized using the HRP and 
DAB provided in the kit.  Slides were counterstained with hematoxylin. Tissue from normal 
mouse prostate was used as a positive control for E-cadherin and a negative control for N-
cadherin. Mouse cardiac muscle was used as a positive control for N-cadherin and a negative 
control for E-cadherin. Slides were scanned with a NanoZoomer 2.0-HT digital slide scanner 
(Hamamtsu, Bridgewater, NJ) with Olympus Uplansapo 20x objective at 40x digital zoom, 
giving 0.23µm resolution.  Images were captured with NDP view software (Hamatsu). 
Real-Time quantitative PCR. Prostatic mRNA was extracted from mice with well-
differentiated adenocarcinoma in the dorsolateral prostate (n=8/group).  Total RNA was isolated 
with the RNeasy Mini Kit (Qiagen, Valencia, CA) and on-column DNAse treated with an 
RNAse free-DNAse kit (Qiagen). Total RNA (400ng) was reverse transcribed to first-strand 
complementary DNA (cDNA) with a RT
2
 First Strand Kit (SABiosciences, Frederick, MD) 
according to the manufacturer’s instructions.  Expression of 84 genes was measured with Mouse 
Epithelial to Mesenchymal Transition RT² Profiler™ PCR Arrays (SA Biosciences) (Table A.6). 
Reactions contained RT
2
 SYBR Green ROX
TM
 qPCR Mastermix (Qiagen) and were monitored 
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with ABI Prism 79000HT (Applied Biosystems, Foster City, CA). Data were analyzed using the 
RT² Profiler PCR Array Data Analysis Template v3.5 online software provided by 
SABiosciences (http://www.SABiosciences.com/pcrarraydataanalysis.php).   
Genes of interest identified from the array were validated with a larger sample size and 
individual qRT-PCR reactions. RNA was extracted and DNAse treated as described above and 
synthesized into cDNA by a High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA). mRNA expression was measured with RT² qPCR Primer Assays 
(Qiagen) using RT
2
 SYBR Green ROX
TM
 qPCR Mastermix (Qiagen) and monitored with ABI 
Prism 79000HT (Applied Biosystems). GAPDH was used as a housekeeping gene, and relative 
mRNA abundance was determined using the 2^-ΔΔCt method.  
Statistical analysis. Statistical analyses were conducted using SAS (version 9.3; SAS 
Institute, Cary, NC).  Differences in fold change of mRNA abundance were analyzed by one-
way analysis of variance (ANOVA) followed by Dunnett’s post-hoc test.  Immunohistochemical 
images were used for qualitative information.  
RESULTS AND DISCUSSION 
E-cadherin and N-cadherin expression changes are predictive of metastasis in TRAMP 
mice. The “cadherin switch”, defined as a gain in N-cadherin expression and a loss of E-cadherin 
expression, is a critical hallmark of EMT and may promote metastasis of PCa in humans (5).  
Immunohistochemical analysis of E-cadherin and N-cadherin in the prostate of TRAMP mice 
was measured across a range of pathology is to determine if changes in expression correlate with 
an increased risk of metastasis in the TRAMP model. There was distinct, membranous staining 
of E-cadherin in the benign prostate of non-transgenic mice (Figure 4.1A) with little N-cadherin 
expression (Figure 4.1E). Membranous N-cadherin expression was identified in well- and 
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moderately-differentiated cancer lesions (Figure 4.1F), and while some membranous staining of 
E-cadherin was still evident, expression was weaker than that of benign prostate (Figure 4.1B). 
Poorly-differentiated tumors had positive, membranous N-cadherin staining (Figure 4.1G), but 
weak, aberrant E-cadherin expression (Figure 4.1C).  As expected, the weakest E-cadherin 
staining and strongest N-cadherin staining was seen in poorly-differentiated tumors that had 
metastasized to the pelvic lymph nodes (Figures 4.1D and 4.1H). Reduced E-cadherin 
expression and the robust gain in N-cadherin expression as severity of pathology increases 
suggests that the “cadherin-switch” occurs in the TRAMP model and is predictive of metastasis. 
No effect of broccoli consumption on prostate cancer incidence. At 20 weeks of age, 
PCa incidence, defined as the presence of well-, moderately-, or poorly-differentiated PCa, was 
97% in the controls, 100% in the standard broccoli and 97% in the MeJa group (Figure 4.2). The 
most severe lesions in the TRAMP prostate were primarily in the lateral lobe, which is consistent 
with the defined pathogenesis in this model (17). A few poorly-differentiated carcinoma lesions 
were identified, but well-differentiated adenocarcinoma lesions were the majority of the severe 
lesions in the prostate.  Mice chosen for mRNA analysis all had well-differentiated 
adenocarcinoma in the lateral prostate lobe.  
Expression of markers of the epithelial-to-mesenchymal transition in TRAMP mice 
are altered by broccoli consumption. Although PCa incidence was not reduced by broccoli 
consumption, it was of interest to determine if the molecular profile of the cancer from mice that 
consumed broccoli might indicate a less aggressive disease with a reduced risk of metastasis. Out 
of the 84 genes analyzed in the EMT-focused array, 8 genes were down-regulated and 50 genes 
were up-regulated by at least 1.5 fold in the prostate of control-fed TRAMP mice compared to 
normal, wild-type prostate (Table 4.1). Transcription factors known to induce EMT (Twist1, 
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Snail, Zeb1, Zeb2, TGFβ-1, Sox10, Notch1), facilitators of cytoskeletal remodeling (Fn1, Colla2, 
Col3a1), metalloproteinases (Mmp2 and Mmp9), and N-cadherin (Cdh2) were some of the genes 
up-regulated in TRAMP mice. Findings from the profiler array suggest that markers of EMT 
were evident in the prostates of TRAMP mice with well-differentiated adenocarcinoma.  
Compared to control-fed TRAMP mice, the consumption of standard or MeJa broccoli 
altered the expression of several EMT-related genes (Figure 4.3). In the EMT-focused arrays, 
expression of a few genes were robustly changed by broccoli consumption compared to the 
controls (Table 4.2). Many genes that are down-regulated in EMT such as the epithelial cell 
adhesion proteins Ocln, Dsp, F11r and Cdh1 were upregulated in TRAMP mice that consumed 
broccoli compared to control-fed TRAMP mice.  MeJa broccoli up-regulated expression of E-
cadherin (Cdh1) by nearly 2-fold, but no change in expression was seen in by standard broccoli. 
As listed in Table 4.2, many genes that are normally up-regulated in EMT, such as transcription 
factors that induce EMT (Snai2, Sox 10, Gsc, Twist, Nodal), mesenchymal cell proteins (Cdh2, 
Vim), and matrix metalloproteinases (Mmp3, Mmp9), were down-regulated in TRAMP mice 
that consumed broccoli compared to control-fed TRAMP mice.  Thus, even within the same 
cancer stage, these diets altered the molecular profile of the PCa.   
N-cadherin, but not E-cadherin expression is significantly altered by broccoli 
consumption. Increased N-cadherin expression and reduced E-cadherin expression is a major 
hallmark of EMT (18), and as previously identified, is associated with cancer progression in 
TRAMP mice.  The focused arrays identified that both standard and MeJa broccoli diets reduced 
expression of N-cadherin compared to the controls (Figure 4.3).  Single gene qRT-PCR was 
used to validate changes in cadherin expression identified from the arrays.  E-cadherin 
expression was not significantly up-regulated by either standard or MeJa broccoli (Table 4. 3).  
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Compared to the controls, prostatic N-cadherin expression was down-regulated more than two-
fold in mice that consumed standard broccoli (p=0.04) or MeJa broccoli (p=0.02). The ability of 
broccoli consumption to reduce N-cadherin expression may be a mechanism by which broccoli 
could inhibit EMT. Interestingly, MeJa broccoli did not provide any additional benefit compared 
to standard broccoli, suggesting that that standard broccoli contained a sufficient amount of 
bioactives to alter cadherin expression or that bioactive components other than indole-
glucosinolates may modulate these proteins.  
Broccoli consumption does not alter expression of modulators of cadherin 
expression.  The transcription factors Snail, Slug, and Twist are known inducers of EMT (5); 
however, expression was not modulated by either of the broccoli diets (Table 4.3).   
DISCUSSION 
This is the first study, to our knowledge, to investigate the ability of a dietary intervention 
with broccoli to modulate markers of EMT in vivo. In this study, broccoli consumption reduced 
expression of markers of EMT, particularly N-cadherin, in TRAMP mice.  We identified in the 
TRAMP model a loss of E-cadherin and gain in N-cadherin expression in more severe stages of 
pathology. 
Although the mechanism of reduced N-cadherin expression by broccoli consumption was 
not elucidated in this trial; there are several potential mechanisms that were not investigated.  
EMT is transient and reversible, which suggests that expression of genes associated with EMT 
may be partially modulated by epigenetic mechanisms (19). Histone deacetylases (HDAC) are 
often overexpressed in PCa, resulting in decreased transcription of tumor suppressing genes (20). 
An HDAC inhibitor reduced PCa cell migration, invasion and cell adhesion to extracellular 
matrix proteins in vitro (21, 22). Inhibition of HDAC expression and/or activity may prevent 
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EMT and subsequent metastasis. Consumption of sulfurophane significantly reduced tumor 
growth and HDAC activity in a murine model of PCa (23).  In a sample of healthy adults, a 
single dose of broccoli sprouts significantly reduced HDAC activity in peripheral blood 
mononuclear cells (23).  Methylation of CpG rich islands on promoter regions by DNA 
methyltransferases (DNMT) can result in gene silencing, and reduced E-cadherin expression in 
PCa progression has been correlated with hypermethylation of its promoter region (20).  The 
broccoli bioactives sulforophane and phenethyl isothiocyanate reduced expression of DNMTs in 
PCa cells, resulting in the demethlyation and increased expression of tumor suppressors in vitro 
(24, 25).  Effects on DNA methylation and HDAC expression may be mechanisms by which 
broccoli consumption modulates expression of markers of EMT in PCa and should be further 
investigated.  In this study, the EMT-focused arrays identified a robust reduction in the 
expression of transcription factors Sox10 and Gsc by broccoli consumption, and these genes 
should be further validated by single gene qRT-PCR. Wnt, Hedgehog, TGF-β and TNFα 
signaling pathways, growth factors, hypoxia, steroid hormones and epigenetic mechanisms are 
just a few of the numerous modulators of EMT in PCa (5); therefore, it may be difficult to 
identify the exact mechanism by which whole broccoli, a complex mixture of multiple bioactive 
compounds, may inhibit EMT.  
Findings from clinical studies suggest that regardless of cancer stage, expression of 
markers of EMT is predictive of reduced survival and increased risk of metastasis (6, 15).   In 
this study, all prostates used for qRT-PCR analyses had well-differentiated adenocarcinoma and 
our findings suggest that even within the same cancer stage, diet can modulate the expression of 
genes associated with cancer progression and a more aggressive disease. Future studies should 
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investigate the mechanism of reduced N-cadherin expression by broccoli consumption and 
whether these changes could translate to reduced risk of metastasis of existing PCa. 
 
FIGURES AND TABLES 
Table 4.1. Prostatic mRNA expression of EMT-related genes up-regulated in TRAMP mice 
(n=5) compared to C57BL/6 wild-type mouse (n=1).  
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Table 4.2. EMT-related genes modulated in TRAMP mice by broccoli consumption compared to 
control-fed mice 
 
Standard Broccoli MeJa Broccoli 
Gene 
Fold 
Regulation1 
Gene 
Fold 
Regulation1 
Gene 
Fold 
Regulation1 
Gene 
Fold 
Regulation1 
Dsc2 fg 1.2 Bmp7 a -1.6 Cdh1 fg 2.0 Bmp7 a -1.3 
Dsp fg 2.1 Cald1 e -1.1 Dsc2 fg 1.1 Cald1 e -1.3 
F11r fg 1.2 Cdh2 d -2.2 Dsp fg 1.1 Cdh2 d -3.0 
Fgfbp1  f 1.1 Col1a2 b -1.2 Fgfbp1  f 1.6 Esr1 a -1.2 
Mst1r  f 1.1 Col3a1 b -1.2 Il1rn f 1.2 Gsc a -1.7 
Ocln fg 1.2 Col5a2 b -1.1 Mst1r  f 1.1 Mmp9 c -1.1 
Pppde2 f 1.2 Gsc a -2.7 Ocln fg 1.1 Nodal a -1.3 
  
Mmp3 c -2.4 Pppde2  f 1.1 Rac1 abe -1.1 
  
Mmp9 c -1.1 Spp1  f 2.0 Snai2 a -1.2 
  
Msn 
e
 -1.1 Tfpi2  
f
 1.6 Sox10 
a
 -2.4 
  
Nodal a -1.2 
  
Tgfb2 ae -1.1 
  
Pdgfrb ae -1.1 
  
Twist1 a -1.1 
  
Rac1 abe -1.1 
  
Wnt5b a -1.3 
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    1 Fold regulation compared
 
to control-fed TRAMP mice. 
a 
Transcription factors and signaling pathways that induce EMT 
b 
facilitators of cytoskeleton remodeling 
c
 Matrix metalloproteinases 
d
 Mesenchymal cell proteins 
e
 Facilitators of migration and motility 
f
 Genes down-regulated during EMT 
g
 Epithelial cell adhesion proteins 
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Table 4.3. Prostatic mRNA Expression in Well-Differentiated Adenocarcinoma 
 E-cadherin N-cadherin Snail Slug Twist 
AIN-93G 1.0 ± 0.1 1.0 ± 0.3  1.0 ± 0.3 1.0 ± 0.2 1.0 ± 0.3 
10% Standard Broccoli 1.2 ± 0.1  0.4 ± 0.1 * 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 
10% MeJa Broccoli 1.1 ± 0.1 0.4 ± 0.1 * 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 
Values are expressed as fold change relative to the control which was set to 1. n=8-10.  
*within column indicates significantly different than control (p<0.05). 
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Figure 4.1. Immunohistochemical staining of E-cadherin and N-cadherin in untreated mouse 
prostate. 
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Figure 4.1 (continued): E-cadherin (A-D) and N-cadherin (E-H) staining in benign prostate of 
wild-type mice (A and E), well- to moderately-differentiated cancer in TRAMP mice (B and F), 
poorly-differentiated tumor without metastasis (C and G) and poorly-differentiated tumor that 
metastasized to pelvic regional lymph nodes (D and H). Observe progressively stronger 
membranous staining of N-cadherin and weaker membranous staining of E-cadherin in prostate 
cancer progression. Not that the weak cytoplasmic staining of N-cadherin in wild-type prostate is 
nonspecific, background staining.  
 
Figure 4.2. Analysis of histopathological data based upon the most severe lesion found in the 
entire prostate for TRAMP mice fed control diet, standard broccoli, or MeJa broccoli. 
 
 
 
 
 
 
 
 
 
 
n=32-33/group. 
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Figure 4.3. EMT-related gene expression heat map indicates a shift in the prostatic expression 
profile of TRAMP mice consuming broccoli.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: AIN93-G (control), B: Standard Broccoli, C: MeJa Broccoli. n=5/group. 
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CHAPTER 5 
SUMMARY AND FUTURE DIRECTIONS 
 
There is a growing body of scientific evidence identifying potential bioactive compounds 
and anti-carcinogenic properties of fruits and vegetables.  In addition, the utilization of a 
combination of foods for cancer prevention has gained significant interest. Whole foods are a 
complex matrix of a mixture of nutrients and bioactives, and assumptions regarding the 
bioavailability and efficacy of bioactives when consumed in combination with other foods 
should not be made.  Although tomato carotenoids and soy germ isoflavones have distinctly 
different mechanisms of absorption, we determined that combined consumption of tomato and 
soy germ resulted in significantly lower serum and tissue accumulation of tomato carotenoids 
(Chapters 2 and 3). The mechanism of reduced carotenoid bioaccumulation was not identified, 
but due to the complexity of potential interactions between the numerous bioactives in whole 
foods, this may continue to be a difficult mechanism to elucidate. However, our findings 
emphasize the importance of preclinical trials to assess the bioavailability of the bioactives of 
interest and potential interactions between functional foods that could impact the potential 
efficacy of dietary interventions.  
Our findings of reduced cancer incidence by TP and SG consumption (Chapter 3) support 
a large body of evidence that suggests bioactive compounds in these foods have anti-
carcinogenic properties. While this preclinical trial had several novel findings, further research is 
still needed before translation to clinical recommendations. Future trials should investigate 
mechanisms by which TP and SG are protective, varying doses of TP and SG, and whether equol 
production is required for the benefits of soy germ. 
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The consumption of daidzein rich soy germ resulted in the production of the bioactive 
metabolite (S)-equol in rodents (Chapters 2 and 3).  TRAMP mice that consumed soy germ 
produced equol, which was over 80% and 50% of total isoflavones in the serum and prostate, 
respectively. However, it is estimated that only one-third of the Western population possess the 
intestinal microbiota that can metabolize daidzein to equol. Non-equol producers may never gain 
the ability to produce equol after isoflavone consumption; therefore, it is critical to determine if 
non-equol producers would still benefit from consumption of soy germ. Numerous intervention 
trials with soy products have stratified results by equol and non-equol producers; however, it 
continues to be unclear whether equol production is required for the benefits of soy consumption 
(1).  Although equol was the predominant isoflavone in the serum and prostate of TRAMP mice, 
other isoflavones and phytochemicals in soy germ may have worked synergistically together to 
elicit protection against PCa. The parent isoflavone daidzein was approximately 17% of total 
isoflavones in the prostate of TRAMP mice consuming soy germ; therefore, the parent 
isoflavone, rather than only its metabolite equol may also have direct activity in the prostate. An 
animal trial to examine the efficacy of soy germ in equol and non-equol producers would require 
germ free animals, as rodents are extremely efficient equol producers. Another approach would 
be to compare PCa incidence in TRAMP mice consuming soy germ and TRAMP mice 
consuming the same amount of daidzein aglycone equivalent found in soy germ.  If the health 
benefits from soy germ are dependent on equol production, future clinical trials with soy germ 
may need to consider including only equol producers. 
A novel finding in the TRAMP tomato and soy germ study worth noting is that 
physiologically relevant amounts of tomato and soy germ were effective at reducing PCa 
incidence. The Food and Drug Administration suggests that translation of an animal dose to 
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human dose should be done through normalization to body surface area (BSA) with a calculation 
of: Human equivalent dose (mg/kg) = Animal dose (mg/kg) multiplied by Animal Km/Human 
Km (2). In the TRAMP tomato and soy germ trial, the average consumption of 5.7 grams of 
experimental diet a day provided 2.3mg isoflavone aglycone equivalents (soy germ containing 
diets) and 1.5mg of lycopene (tomato powder containing diets). Based on the BSA calculation, 
the human equivalent dose (HED) of what was provided in the experimental diets is 5.3mg 
isoflavone aglycone equivalents/kg body weight and 3.5mg lycopene/kg body weight, which 
translates to a 70kg male consuming 373mg isoflavones or 245mg lycopene.   Intake of a 
purified supplement providing 600mg isoflavones/day in men with PCa for 56 days (3) and 84 
days (4) has previously been shown to be safe, with no evidence of significant toxicity or 
genotoxicity. Although the calculated HED of isoflavones has been shown to be safe, this dose is 
difficult to achieve through consumption of soy foods. However, the extrapolation of a dose from 
a preclinical dietary intervention trial must consider the food matrix and the differences in 
absorption and metabolism between rodents and humans.  
Long term consumption of experimental diets resulted in bioaccumulation of soy germ 
and tomato phytochemicals; therefore, translation to a human equivalent dose may best be 
determined through comparison of serum and tissue concentrations.  Isoflavone concentrations in 
the serum (~4µM) and prostate (0.20 nmol/g) of TRAMP mice were comparable to what has 
been identified in men consuming soy foods. In a small clinical trial, consumption of soy foods 
providing 96 mg isoflavones/day for only six days resulted in total serum isoflavone 
concentrations greater than 4µM (5). Asian populations, which have a substantially lower 
incidence of PCa compared to Western countries (6), consume an average of 25-50 mg 
isoflavones/day (7), equivalent to approximately 2-3 servings of soy foods (one serving = 4 oz 
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tofu, 1 oz soy nuts or 8 oz soymilk).  A study in Korean men reported prostatic isoflavone 
concentrations of over 0.4 nmol/g (8), which is even higher than what was achieved in our trial 
(~0.2 nmol/g). Therefore, based on comparison of serum and tissue isoflavone concentrations in 
TRAMP mice, translation of the amount of isoflavones provided in soy germ is roughly 
equivalent to 2-3 servings of soy foods a day. Lycopene concentrations in the serum (0.36 – 0.84 
µM) and prostate (0.11 – 0.48 nmol/g tissue) of TRAMP mice are comparable to levels observed 
in men consuming 25-30 mg lycopene/day from tomato products (9-11), which can be achieved 
by intake of approximately one cup of tomato sauce, ½ cup tomato paste or 6 cups of raw 
tomatoes. Therefore, the tissue and serum concentrations of lycopene achieved in the study can 
be obtained in humans by intake of whole foods. 
Only one level of soy germ and tomato powder was investigated in our trial, and it is of 
interest to determine the efficacy of other doses to identify a potential dose response. In the 
TRAMP model, diets containing 250mg, 500mg, and 1000mg genistein/kg diet were effective in 
reducing the incidence and progression of PCa, with the higher doses being more effective (12-
17), suggesting a dose response. Carotenoids are transported in the blood by lipoproteins, and 
studies suggest that serum carotenoid concentrations eventually plateau. A previous study in our 
laboratory found that serum lycopene was not significantly different between rats receiving 
dietary lycopene supplementation of 0.05 or 0.50 g/kg diet after 8 weeks (18), suggesting a 
saturation point in the blood. In men with PCa, lycopene supplementation increased plasma 
lycopene levels that reached a plateau at 3 months and remained stable for the duration of the 12-
month intervention (19).  Future trials should examine a range of doses of tomato and soy germ, 
alone and in combination, to identify the most effective dose for translation to clinical trials.  
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The majority of preclinical and clinical intervention trials with soy have utilized soy 
protein isolate; however, the efficacy of this soy product should not be extrapolated to all soy 
products. Soy germ has never previously been investigated in a cancer prevention trial. We 
identified that long term consumption of soy germ significantly reduced the incidence of PCa in 
TRAMP mice by nearly 35%, providing evidence that this soy product may also have anti-cancer 
activity. In our trials (Chapters 2 and 3), no adverse effects were identified from long term 
consumption (14 and 24 weeks) of soy germ. Our research identified that in rodent models, soy 
germ isoflavones are bioavailable, undergo further metabolism to potential bioactive metabolites, 
and accumulate in the prostate.  Due to soy germ’s high concentration of soy phytochemicals, 
only small amounts of this product are needed to enhance the phytochemical content of a food 
and can be easily utilized for development of functional food products.  Long term 
supplementation of SoyLife® soy germ products has shown to be safe in both women (20) and 
men (21). In fact, a tomato juice with soy germ isoflavones has already been developed and 
tested for safety in men with PCa (22).  In general, experimental evidence suggests that 
consumption of soy germ products and/or supplements can be considered safe and may also have 
anti-cancer activity. 
The main endpoint of the preclinical PCa trial was to determine the effect of diet on 
cancer incidence, and evaluation of potential mechanisms requires a different study design. A 
similar study design with animals euthanized at earlier time points would be valuable in 
identifying the effects of diet on early stages of carcinogenesis. Tomato and soy germ may work 
through both common and different anti-carcinogenic mechanisms with potential synergistic 
activity.  Due to the numerous potential transcriptional, translational, and post-translational 
mechanisms by which tomato or soy bioactives may modulate carcinogenesis, a more global 
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examination of changes on cancer processes must be utilized. High-throughput screening with 
genomic, proteomic, and metabolic technologies combined with bioinformatics can provide a 
more comprehensive examination of potential mechanisms rather than measuring a few known 
biomarkers of carcinogenesis. Although our novel finding of greater benefit by the combination 
of tomato and soy germ is significant, there are many future directions for this project that should 
be pursued before direct translation in to clinical recommendations.  
The epithelial to mesenchymal transition (EMT) is a key biological pathway involved in 
metastasis. Although broccoli consumption did not reduce the incidence of PCa in TRAMP 
mice, mRNA expression of markers of EMT were altered by broccoli consumption (Chapter 4). 
This is the first in vivo study to investigate the ability of a dietary intervention with broccoli to 
modulate markers of EMT in PCa. Expression of N-cadherin, a mesenchymal cadherin that is 
crucial in PCa progression to hormone-refractory metastatic disease, was significantly lower in 
TRAMP mice that consumed broccoli. In vitro and in vivo, inhibition of N-cadherin by targeted 
antibodies prevented PCa metastasis and progression to hormone-refractory disease (23). 
Therefore, our findings suggest that even within the same cancer stage, diet can have a 
significant impact on the molecular profile of a cancer, and targeting N-cadherin and other EMT 
related proteins may have a significant clinical impact on cancer progression.   
Although the mechanism of reduced N-cadherin expression by broccoli consumption was 
not explained in our study, there are several potential mechanisms that can be investigated in 
future trials.  Expression of genes associated with EMT may partially be controlled by epigenetic 
mechanisms (24), and in vitro and in vivo evidence suggests that broccoli bioactives may 
modulate expression of histone deacetylases (HDAC) and DNA methyltransferases (DNMT). 
There is some experimental evidence to suggest that broccoli bioactives may reduce the risk of 
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PCa invasion and metastasis, but the combination of multiple bioactives in whole broccoli has 
not previously been investigated with an endpoint of PCa invasion or metastasis. The utilization 
of broccoli extracts or multiple broccoli bioactives at physiologically relevant concentrations 
should be investigated in vitro to provide insight into the potential mechanism by which broccoli 
consumption modulated markers of EMT and whether these changes could translate to reduced 
invasion and metastasis. 
PCa is typically diagnosed later in life and the long latency period between diagnosis and 
potential metastasis provides an ideal therapeutic window for dietary interventions to reduced 
prostate carcinogenesis. In this body of work, interventions with whole foods and combinations 
of foods were demonstrated to be feasible, safe and effective strategies for PCa prevention and 
support a food based approach for reduction of prostate carcinogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
114 
 
References  
1. Lampe JW. Is equol the key to the efficacy of soy foods? Am J Clin Nutr. 2009;89(5):1664S-
7S.  
2. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. 
FASEB J. 2008;22(3):659-61.  
3. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, et al. Lack of 
significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 
patients with prostate cancer. Am J Clin Nutr. 2003;77(4):875-82.  
4. Fischer L, Mahoney C, Jeffcoat AR, Koch MA, Thomas BE, Valentine JL, et al. Clinical 
characteristics and pharmacokinetics of purified soy isoflavones: Multiple-dose administration to 
men with prostate neoplasia. Nutr Cancer. 2004;48(2):160-70.  
5. Gardner CD, Oelrich B, Liu JP, Feldman D, Franke AA, Brooks JD. Prostatic soy isoflavone 
concentrations exceed serum levels after dietary supplementation. Prostate. 2009;69(7):719-26.  
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden 
of cancer in 2008: GLOBOCAN2008. Int J Cancer. 2010;127(12):2893-2917.  
7. Messina M, Nagata C, Wu AH. Estimated asian adult soy protein and isoflavone intakes. Nutr 
Cancer. 2006;55(1):1-12.  
8. Hong SJ, Kim SI, Kwon SM, Lee JR, Chung BC. Comparative study of concentration of 
isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic 
hyperplasia. Yonsei Med J. 2002;43(2):236-41.  
9. Bowen P, Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, et al. Tomato 
sauce supplementation and prostate cancer: Lycopene accumulation and modulation of 
biomarkers of carcinogenesis. Exp Biol Med. 2002;227(10):886-93.  
115 
 
10. Van Breemen RB, Xu X, Viana MA, Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. 
Liquid chromatography - mass spectrometry of cis- and all-trans-lycopene in human serum and 
prostate tissue after dietary supplementation with tomato sauce. J Agric Food Chem. 
2002;50(8):2214-9.  
11. Grainger EM, Schwartz SJ, Wang S, Unlu NZ, Boileau TW, Ferketich AK, et al. A 
combination of tomato and soy products for men with recurring prostate cancer and rising 
prostate specific antigen. Nutr Cancer. 2008;60(2):145-54.  
12. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. Dietary 
genistein improves survival and reduces expression of osteopontin in the prostate of transgenic 
mice with prostatic adenocarcinoma (TRAMP). J Nutr. 2005;135(5):989-95.  
13. El Touny LH, Banerjee PP. Identification of a biphasic role for genistein in the regulation of 
prostate cancer growth and metastasis. Cancer Res. 2009;69(8):3695-703.  
14. El Touny LH, Banerjee PP. Akt GSK-3 pathway as a target in genistein-induced inhibition of 
TRAMP prostate cancer progression toward a poorly differentiated phenotype. Carcinogenesis. 
2007;28(8):1710-7.  
15. Wang J, Eltoum IE, Lamartiniere CA. Genistein chemoprevention of prostate cancer in 
TRAMP mice. J Carcinog. 2007;6:3.  
16. Wang J, Eltoum IE, Lamartiniere CA. Genistein alters growth factor signaling in transgenic 
prostate model (TRAMP). Mol Cell Endocrinol. 2004;219(1-2):171-80.  
17. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the 
diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice 
(TRAMP). Cancer Res. 2001;61(18):6777-82.  
116 
 
18. Boileau TW, Clinton SK, Erdman JW, Jr. Tissue lycopene concentrations and isomer 
patterns are affected by androgen status and dietary lycopene concentration in male F344 rats. J 
Nutr. 2000;130(6):1613-8.  
19. Clark P, Hall MC, Borden L, Miller A, Hu J, Lee WR, et al. Phase I-II prospective dose-
escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive 
local therapy. Urology. 2006;67(6):1257-61.  
20. Steinberg FM, Murray MJ, Lewis RD, Cramer MA, Amato P, Young RL, et al. Clinical 
outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr. 
2011;93(2):356-67.  
21. Thorp AA, Sinn N, Buckley JD, Coates AM, Howe PR. Soya isoflavone supplementation 
enhances spatial working memory in men. Br J Nutr. 2009;102(09):1348-54.  
22. Bohn T, Blackwood M, Francis D, Tian Q, Schwartz SJ, Clinton SK. Bioavailability of 
phytochemical constituents from a novel soy fortified lycopene rich tomato juice developed for 
targeted cancer prevention trials. Nutr Cancer. 2011 11/18; 2013/01.  
23. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, et al. Monoclonal 
antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration 
resistance. Nat Med. 2010;16(12):1414-20.  
24. Talbot LJ, Bhattacharya SD, Kuo PC. Epithelial-mesenchymal transition, the tumor 
microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol. 
2012;3(2):117-36.  
 
  
117 
 
APPENDIX A 
SUPPLEMENTAL TABLES AND FIGURES 
Table A.1. Tissue carotenoid concentration in 7-day feeding 
Carotenoid 10% Tomato 
Powder 
10% Tomato Powder + 2% Soy Germ 
Liver (nmol/g) 
Phytoene 20 ± 2 16 ± 2 
Phytofluene 11 ± 1 9 ± 2 
Lycopene 61 ± 2 52 ± 5 
Ventral Prostate (nmol/g) 
Phytoene ND ND 
Phytofluene 0.017 ± 0.004 0.017 ± 0.005 
Lycopene 0.048 ± 0.006 0.048 ± 0.003 
Testes (nmol/g) 
Phytoene ND ND 
Phytofluene 0.046 ± 0.002 0.046 ± 0.002 
Lycopene 0.075 ± 0.004 0.066 ± 0.004 
Values are means ± SEM. Testes and liver, n=6; ventral prostate, n=3. 
β-carotene below detection limits. 
ND = below detection limits. 
Table A.2. Hepatic lipids and serum cholesterol in 25-week feeding study 
Diet Hepatic Lipids 
(mg/g tissue) 
Serum Cholesterol 
(mg/dL) 
AIN-93G 37.4 ± 2.4  172 ± 12 
10% Tomato Powder 35.7 ± 1.1 160 ± 8 
2% Soy Germ 37.2 ± 2.5 158 ± 6 
10% Tomato Powder + 2% Soy Germ 34.6 ± 2.6 150 ± 3 
Values are means ± SEM.        
Hepatic lipids, n=6; serum cholesterol n=8 
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Table A.3. Hepatic CYP1A and NQO1 activity and expression in 25-week feeding study 
 AIN-93G 10% 
Tomato 
Powder 
2% Soy 
Germ 
10% Tomato 
Powder + 2% Soy 
Germ 
CYP1A Activity* 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 
CYP1A2 Expression 1.0 ± 0.2 1.3 ± 0.2 2.3 ± 0.9 1.4 ± 0.2 
NQO1 Activity 1.0 ± 0.1 1.0 ± 0.2 0.9 ± 0.1 1.2 ± 0.1 
NQO1 Expression 1.0 ± 0.1 1.0 ± 0.1 1.3 ± 0.2 1.2 ± 0.1 
*Activity measured as ethoxyresorufin O-deethylase (EROD) activity  
Values expressed as relative to control (AIN-93G), which was set to 1. 
 Results are mean ± SEM. Enzyme activity n=8, enzyme expression n=8-11.  
Table A.4. Hepatic CYP1A and NQO1 activity and expression in 7-day feeding study 
 AIN-93G 10% Tomato 
Powder 
2% Soy 
Germ 
10% Tomato 
Powder + 2% 
Soy Germ 
CYP1A Activity*    1.0 ± 0.1 
ab
    1.0 ± 0.1 
ab
   0.8 ± 0.1 
a
   1.2 ± 0.1 
b
 
CYP1A2 Expression 1.0 ± 0.3 0.9 ± 0.2 1.5 ± 0.4 1.6 ± 0.4 
NQO1 Activity 1.0 ± 0.2 0.9 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 
NQO1 Expression 1.0 ± 0.2 0.9 ± 0.1 1.4 ± 0.3 1.9 ± 0.4 
*Activity measured as ethoxyresorufin O-deethylase (EROD) activity  
Values expressed as relative to control (AIN-93G), which was set to 1.  
Results are mean ± SEM, n= 6.  
Different letters within rows indicate significant differences between treatments (p<0.05).  
Table A.5. Urinary isoflavone recovery
1
 in 25-week feeding study 
 % Recovery 
Daidzein 
% Recovery 
Genistein 
% Recovery 
Glycitein 
% Recovery  
Total Isoflavones 
2% Soy Germ 14.7 ± 5.4 14.9 ± 3.5 9.1 ± 2.7 35.8 ± 12.0 
10% Tomato 
Powder + 2% Soy 
Germ 
21.0 ± 2.4 16.0 ± 1.5 15.7 ± 3.4 47.9 ± 5.9 
1
Urinary isoflavone recovery = micromoles of isoflavone excreted in urine in 24 
hours/micromoles of isoflavone consumed in 24 hours. 
Results are mean ± SEM, n=5-6.  
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Table A.6. Gene table for epithelial to mesenchymal transition arrays 
NCBI Reference 
Sequence Symbol Description 
NM_001039959 Ahnak AHNAK nucleoprotein (desmoyokin) 
NM_009652 Akt1 Thymoma viral proto-oncogene 1 
NM_009755 Bmp1 Bone morphogenetic protein 1 
NM_007557 Bmp7 Bone morphogenetic protein 7 
NM_145575 Cald1 Caldesmon 1 
NM_025451 Camk2n1 Calcium/calmodulin-dependent protein kinase II inhibitor 1 
NM_016900 Cav2 Caveolin 2 
NM_009864 Cdh1 Cadherin 1 
NM_007664 Cdh2 Cadherin 2 
NM_007743 Col1a2 Collagen, type I, alpha 2 
NM_009930 Col3a1 Collagen, type III, alpha 1 
NM_007737 Col5a2 Collagen, type V, alpha 2 
NM_007614 Ctnnb1 Catenin (cadherin associated protein), beta 1 
NM_013505 Dsc2 Desmocollin 2 
NM_023842 Dsp Desmoplakin 
NM_007912 Egfr Epidermal growth factor receptor 
NM_010153 Erbb3 V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 
NM_007956 Esr1 Estrogen receptor 1 (alpha) 
NM_172647 F11r F11 receptor 
NM_008009 Fgfbp1 Fibroblast growth factor binding protein 1 
NM_010233 Fn1 Fibronectin 1 
NM_013519 Foxc2 Forkhead box C2 
NM_008057 Fzd7 Frizzled homolog 7 (Drosophila) 
NM_025331 Gng11 Guanine nucleotide binding protein (G protein), gamma 11 
NM_010351 Gsc Goosecoid homeobox 
NM_019827 Gsk3b Glycogen synthase kinase 3 beta 
NM_010517 Igfbp4 Insulin-like growth factor binding protein 4 
NM_031167 Il1rn Interleukin 1 receptor antagonist 
NM_010562 Ilk Integrin linked kinase 
NM_010577 Itga5 Integrin alpha 5 (fibronectin receptor alpha) 
NM_008402 Itgav Integrin alpha V 
NM_010578 Itgb1 Integrin beta 1 (fibronectin receptor beta) 
NM_013822 Jag1 Jagged 1 
NM_016958 Krt14 Keratin 14 
NM_008471 Krt19 Keratin 19 
NM_033073 Krt7 Keratin 7 
NM_008601 Mitf Microphthalmia-associated transcription factor 
NM_008610 Mmp2 Matrix metallopeptidase 2 
NM_010809 Mmp3 Matrix metallopeptidase 3 
NM_013599 Mmp9 Matrix metallopeptidase 9 
NM_010833 Msn Moesin 
NM_009074 Mst1r Macrophage stimulating 1 receptor (c-met-related tyrosine kinase) 
NM_008634 Mtap1b Microtubule-associated protein 1B 
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Table A.6 (cont.) 
NM_013611 Nodal Nodal 
NM_008714 Notch1 Notch gene homolog 1 (Drosophila) 
NM_026341 Nudt13 Nudix (nucleoside diphosphate linked moiety X)-type motif 13 
NM_008756 Ocln Occludin 
NM_008809 Pdgfrb Platelet derived growth factor receptor, beta polypeptide 
NM_013738 Plek2 Pleckstrin 2 
NM_134095 Pppde2 PPPDE peptidase domain containing 2 
NM_007982 Ptk2 PTK2 protein tyrosine kinase 2 
NM_011200 Ptp4a1 Protein tyrosine phosphatase 4a1 
NM_009007 Rac1 RAS-related C3 botulinum substrate 1 
NM_009061 Rgs2 Regulator of G-protein signaling 2 
NM_008871 Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1 
NM_025656 Sip1 Survival of motor neuron protein interacting protein 1 
NM_010754 Smad2 MAD homolog 2 (Drosophila) 
NM_011427 Snai1 Snail homolog 1 (Drosophila) 
NM_011415 Snai2 Snail homolog 2 (Drosophila) 
NM_013914 Snai3 Snail homolog 3 (Drosophila) 
NM_011437 Sox10 SRY-box containing gene 10 
NM_009242 Sparc Secreted acidic cysteine rich glycoprotein 
NM_009263 Spp1 Secreted phosphoprotein 1 
NM_011486 Stat3 Signal transducer and activator of transcription 3 
NM_027399 Steap1 Six transmembrane epithelial antigen of the prostate 1 
NM_009332 Tcf7l1 Transcription factor 7-like 1 (T-cell specific, HMG box) 
NM_013685 Tcf4 Transcription factor 4 
NM_009364 Tfpi2 Tissue factor pathway inhibitor 2 
NM_011577 Tgfb1 Transforming growth factor, beta 1 
NM_009367 Tgfb2 Transforming growth factor, beta 2 
NM_009368 Tgfb3 Transforming growth factor, beta 3 
NM_011593 Timp1 Tissue inhibitor of metalloproteinase 1 
NM_021436 
Tmeff1 
Transmembrane protein with EGF-like and two follistatin-like 
domains 1 
NM_133804 Tmem132a Transmembrane protein 132A 
NM_025359 Tspan13 Tetraspanin 13 
NM_011658 Twist1 Twist homolog 1 (Drosophila) 
NM_001081249 Vcan Versican 
NM_011701 Vim Vimentin 
NM_173028 Vps13a Vacuolar protein sorting 13A (yeast) 
NM_009519 Wnt11 Wingless-related MMTV integration site 11 
NM_009524 Wnt5a Wingless-related MMTV integration site 5A 
NM_009525 Wnt5b Wingless-related MMTV integration site 5B 
NM_011546 Zeb1 Zinc finger E-box binding homeobox 1 
NM_015753 Zeb2 Zinc finger E-box binding homeobox 2 
 
